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Resumo 
 
Uma das características dos tumores sólidos e das células tumorais, é o designado “efeito 
de Warburg”, no qual as células obtêm energia a partir da glicólise, mesmo na presença de 
altas concentrações de oxigénio, levando à produção aumentada de lactato. O efluxo de 
lactato para o meio extracelular induz acidificação, condiciona o ambiente tumoral, que 
favorece a invasão e suprime a resposta imune anti-tumoral, o qual é correlacionado com mau 
prognóstico clínico. Deste modo, torna-se importante o estudo de moléculas como os 
transportadores de monocarboxilatos (MCTs) cuja função nos tumores está associada ao 
transporte de ácidos monocarboxílicos relevantes, como o lactato por co-transporte com 
protão (mecanismo de simporte), através da membrana plasmática. Sendo assim, é de esperar 
que estes transportadores estejam sobre-expressos em tumores, de forma a manterem as 
elevadas taxas de glicólise, prevenindo a apoptose por acidificação intracelular. No cancro de 
mama, a sobre-expressão do MCT1 foi associada com o fenótipo agressivo, como o carcinoma 
da mama do tipo basal.  
Assim, foram realizados estudos in vitro em linhas celulares do carcinoma da mama, para 
avaliar o efeito da inibição dos MCTs pela Quercetina e Lonidamina, na biomassa total, 
metabolismo, proliferação, morte, migração e invasão celular. 
Neste estudo, mostrou-se que a alteração do metabolismo glicolítico através da inibição 
dos MCTs diminui a agressividade das linhas celulares do carcinoma da mama. A Quercetina e 
a Lonidamina inibiram o efluxo de lactato nas células que expressam MCT1 na membrana e 
diminuíram a proliferação celular e induziram morte celular nas células positivas para MCT1. 
Além disso, a capacidade de migração e invasão celular foi também reduzida com ambos os 
tratamentos. 
Estes resultados evidenciam a importância dos MCTs,  especialmente do MCT1, em células 
do carcinoma da mama, nomeadamente do tipo basal. 
 
 
 
 
 
Palavras-chave: “Efeito de Warburg”, Transportadores de Monocarboxilatos (MCTs), Quercetina, 
Lonidamina, Carcinoma da Mama.
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Abstract 
 
One of the essential hallmarks of solid tumours and tumour cells is known as the “Warburg 
effect”, in which cells obtain energy from glycolysis, even in the presence of oxygen, leading to 
increase in lactate production. Lactate efflux induces extracellular acidification, promotes 
invasion and suppresses anti-tumour immune response, which is correlated with poor clinical 
prognostic. Thus, it becomes important to study molecules such as monocarboxylate 
transporters (MCTs) whose function in tumours is associated with the transport of important 
monocarboxylates, such as lactate, by a cotransport with protons (symport mechanism) 
through the plasma membrane. Therefore, it is expected that MCTs are upregulated in 
tumours, in order to maintain high rates of glycolysis, preventing apoptosis by intracellular 
acidification. In breast cancer MCT1 over-expression was associated with aggressive 
phenotype, such as basal-like breast carcinoma. 
Thus, in vitro studies using breast cancer cell lines were performed to assess the effect of 
MCTs inhibition by Quercetin and Lonidamine, in cell total biomass, metabolism, proliferation, 
death, migration and invasion. 
In this study, it was shown that the disturbance of tumour cell glycolytic metabolism 
through inhibition of MCTs decreased the aggressiveness of human breast cancer cell lines. 
Quercetin and Lonidamine inhibited lactate efflux in cells with MCT1 plasma membrane 
expression and decreased proliferation and induced cell death in MCT1 positive cells. Also, cell 
migration and invasion capacity was reduced by both treatments. 
These findings provide novel evidence for the role of MCTs, mainly MCT1, in breast cancer 
cells, especially in the basal-like subtype. 
 
 
 
 
 
 
 
 
Key words: “Warburg Effect”, Monocarboxylate Transporters (MCTs), Quercetin, Lonidamine, Breast 
Carcinoma 
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1.1. Cell Metabolism 
 
Cell metabolism is a highly coordinated cellular activity in which many metabolic pathways 
cooperate to convert nutrient molecules into other molecules required for specialized cellular 
functions, to obtain chemical energy for vital processes [1]. 
Glucose plays a central role in cell metabolism and seems to be an excellent fuel and a 
versatile precursor, capable of providing a vast group of metabolic intermediates for 
biosynthetic reactions. This molecule has three most important fates: it may be stored; 
oxidized to pyruvate via glycolysis and subsequent oxidative phosphorylation (OXPHOS) to 
supply ATP and metabolic intermediates; or oxidized via the pentose phosphate pathway (PPP) 
to produce ribose 5-phosphate for nucleic acid synthesis and NADPH for reductive biosynthetic 
processes [1]. 
In contrast to normal cells, which rely primarily on mitochondrial oxidative 
phosphorylation to generate energy, most cancer cells instead rely on aerobic glycolysis [2]. 
So, in this first part glycolysis and the metabolic alterations that occur in cancer cells will be 
described. 
 
1.1.1. Glycolysis 
 
Glycolysis is a cascade of enzyme-catalyzed reactions that reduce one molecule of glucose 
in two molecules of pyruvate (three-carbon compound), that still contain most of the chemical 
potential energy of glucose [1, 3]. 
Glucose is taken up by the cell by specific transporters (glucose transporter 1 -GLUT1 and 
4-GLUT4), where it is converted first into glucose-6-phosphate by Hexokinase (HK) and then 
into pyruvate, generating 2 molecules of ATP per glucose. Under aerobic conditions (in the 
presence of oxygen), glycolysis is only the first stage in the complete degradation of glucose 
(Figure 1). Pyruvate is then oxidized into Acetyl-CoA, which enters the mitochondrial 
tricarboxylic acid (TCA) cycle. This reaction produces NADH, which then fuels oxidative 
phosphorylation to maximize ATP production, with minimal production of lactate [1, 4-5]. It is 
only in the absence of oxygen (anoxia) or under low oxygen conditions (hypoxia), that 
differentiated cells reduce pyruvate into lactate, via lactic acid fermentation, accepting 
electrons from NADH and thereby regenerating the NAD+ necessary for glycolysis to continue 
[4]. The lactate formed in this reaction, must be exported from the cell, by specific 
transporters, such as Monocarboxylate Transporters (MCTs) [1, 5]. Both processes of glucose 
Introduction   Chapter 1 
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degradation produce protons, which are transported out of the cell causing extracellular 
acidification [5].  
 
 
Figure 1: Glucose metabolism in normal cells. Afferent blood delivers glucose and oxygen (on 
haemoglobin) to tissues, where it reaches cells by diffusion. HbO2- oxygenated haemoglobin [5]. 
 
 
Glycolytic flux is modulated by several effectors to maintain nearly constant ATP levels 
as well as glycolytic intermediates.  ATP creates negative feedback when oxygen is 
abundant and allows mitochondria to further oxidize pyruvate to bicarbonate ion (HCO3
-) 
and then carbon dioxide and water. Several glycolytic enzymes, including Hexokinase, 
Phospho-fructokinase-1 (PFK-1), and Pyruvate Kinase (PK) also suffer allosteric regulation by 
fluctuations in the concentration of key metabolites, like lactate, which reflect the cellular 
balance between ATP production and consumption. On a longer time scale, glycolysis is 
regulated by the hormones glucagon, epinephrine, and insulin, and by changes in the 
expression of the genes for several glycolytic enzymes [1, 3].  
 
NAD
+
 
NADH 
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1.2. Tumour cell metabolism 
 
Cancer is a complex disease involving numerous temporal and spatial changes in cell 
physiology, acquired during its development. Cancer cells differ from healthy cells due to a 
variety of molecular changes, many of which may be associated to metabolic reprogramming. 
Previously, six biological adaptations in tumour cells were proposed: sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis [6]. Recently, four new hallmarks 
have emerged (Figure 2) in which metabolic reprogramming was finally included. 
Reprogrammed energy metabolism as an emerging hallmark was a significant advance to 
understand the complexity of the biology of cancer [7]. 
 
 
 
 
Figure 2: Hallmarks of cancer [7]. 
 
It is now known that cancer cells show various degrees of increased glycolytic rates, 
depending on the cell type and cell growth conditions. Tumours contain well oxygenated 
(aerobic) and poorly oxygenated (hypoxic) regions, regulating the switch from oxidative to 
glycolytic metabolism, respectively [8]. Most tumour cells are localized into intratumoural 
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hypoxia regions, depending on anaerobic glycolysis for ATP production [1]. However some 
tumour cells remain glycolytic even when oxygen availability is restored [9], producing as 
much as 60% of their ATP through this pathway [10], which proceeds about ten times faster 
than in normal tissues [1]. This phenomenon, was characterized by Otto Warburg as a rapid 
conversion the majority of glucose into lactate, even in the presence of sufficient oxygen to 
support mitochondrial oxidative phosphorylation, which is currently known as “aerobic 
glycolysis” or “Warburg effect” [2].  
Persistence of “Warburg effect” is a characteristic of cancer cells and a hallmark of 
advanced cancers [3, 11]. The high increase of glucose uptake by cancer cells is currently the 
basis for clinical use of positron emission tomography (PET) to diagnose tumours as well as to 
monitor therapeutic response in several cancers (Figure 3). Glucose transporters are 
responsible for the uptake of the glucose analogue 2-(18F)-fluoro-2-deoxy-D-glucose (FDG), 
which  after phosphorylation, is not further metabolized and becomes trapped within the cells. 
The accumulation of the radioactive glucose analogue is detected by PET which is able to 
detect tumour cells and differentiate them from normal tissue [11-13]. 
 
 
 
 
 
 
Figure 3: PET imaging with FDG of a patient with lymphoma. The mediastinal nodes (purple arrow) and 
supraclavicular nodes (green arrows) show high uptake of FDG, showing that tumours in these nodes 
have high levels of FDG uptake. The bladder (yellow arrow) also has high activity, because of excretion 
of the radionuclide [5]. 
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In the “Warburg effect”, the conversion of glucose into lactate, generates only around 4 
ATP per molecule of glucose, while in mitochondrial oxidative phosphorylation, complete 
oxidation of one molecule of glucose produces around 30 ATP molecules [4] (Figure 4). Some 
reasons are pointed to explain why tumour cells display high glycolysis and use this less 
energy-efficient pathway to generate ATP: 
 
a) Tumour cells are able to survive in conditions of fluctuating oxygen tension, condition 
that would be lethal for cells that rely mostly on OXPHOS to generate ATP [11, 14]. 
    
b) The acidic microenvironment, mainly due to accumulation of lactate within tumours 
[6], favours tumour progression [15] and suppresses anticancer immune effectors [16]. 
Also, low interstitial pH is associated with upregulation of various angiogenic 
molecules, such as vascular endothelial growth factor (VEGF), which support tumour 
growth, invasion, and metastasis [17]. Moreover, lactate can be taken up by stromal 
cells to regenerate pyruvate that can be either extruded to refuel the cancer cells or 
used for OXPHOS [3]. 
 
c) Tumours can metabolize glucose through the PPP to generate NADPH that ensures the 
cells anti-oxidant defenses against the hostile microenvironment and 
chemotherapeutic agents [5]. 
 
d) Cancer cells use intermediates of the glycolytic pathway for anabolic reactions: glucose 
6-phosphate for glycogen and ribose 5-phosphate synthesis and pyruvate for alanine 
and malate synthesis [5]. Moreover, pyruvate may enter a truncated TCA cycle and the 
resultant Acetyl-CoA is exported from the mitochondrial matrix and becomes available 
for the synthesis of fatty acids, cholesterol, and isoprenoids [11].  
 
 
Some mechanisms have been proposed to explain these increase in glycolysis such as, 
mitochondrial DNA mutations and deletions, nuclear DNA mutations or abnormal gene 
expression, oncogenic transformation, and influence of the tumour microenvironment [10]. 
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Figure 4: Representation of the main differences between oxidative phosphorylation and anaerobic 
glycolysis in differentiated tissues, and aerobic glycolysis in tumours [4]. 
 
 
1.2.1. Tumour microenvironment 
 
Tumour microenvironment is influenced by several key physiological factors: oxygen 
transport, vascular structure/perfusion, nutrient and metabolite transport and pH [17]. A key 
regulator of the glycolytic response, as consequence of tumour hypoxia, is the transcription 
factor hypoxia inducible factor 1 alpha (HIF-1α). This factor participates in genetic regulation 
and signaling cascades that control angiogenesis, invasiveness, oxidative stress resistance, 
treatment-resistance and glycolytic switch to anaerobic metabolism. In some systems, 
constitutively increased HIF-1α levels are associated with high glucose uptake [5, 17], because 
HIF-1α increases expression of GLUT1 and consequently glucose consumption, to compensate 
the smaller ATP production by aerobic glycolysis [8]. HIF-1α also stimulates the synthesis of 
some glycolytic enzymes [1, 8] by transcriptional activation, including: Lactate Dehydrogenase 
A (LDHA), which converts pyruvate to lactate; Pyruvate Dehydrogenase Kinase 1 (PDK1), 
which inactivates the enzyme responsible for conversion of pyruvate to Acetyl-CoA, 
maintaining pyruvate away from mitochondria; and BNIP3, a pro-apoptotic member of Bcl-2 
family that induces selective mitochondrial autophagy (Figure 5). Also, HIF-1α induces the 
expression of proteins that promote the efflux of, the final products of glycolysis, including H+ 
and lactate, like Carbonic Anhydrase IX (CAIX), Sodium-Hydrogen Exchanger 1 (NHE1) and the 
Monocarboxylate Transporters 1 and 4 [8].  
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As described by Sonveaux and colleagues, some tumour cells have the ability to take up 
lactate, through MCT1, and use it for energetic purposes in the presence of O2, in 
mitochondrial oxidative phosphorylation [3] (Figure 4). Lactate can also participate in the 
lactate- alanine shuttle, leading to amino acid synthesis [17]. 
 
 
 
 
 
Figure 5: Intratumoural hypoxia and tumour cell metabolism. LDHA/B- Lactate Dehydrogenase A/B; PDK1-
Pyruvate Dehydrogenase Kinase 1; MCT1/4- Monocarboxylate Transporters 1/4; CA9- Anhydrase IX; NHE1- 
Sodium-Hydrogen Exchanger 1; HIF-1α - hypoxia inducible factor 1 alpha [8]. 
 
 
1.2.2. Contribution of lactate for tumour malignant phenotype 
 
A constitutive and persistent increase in the glycolytic phenotype of tumour cells, results in 
acute and chronic acidification of the local environment. The main cause for acidification of 
Introduction   Chapter 1 
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
10 
the extracellular space is mediated by MCT1 and MCT4 which co-transport H+ and lactate, and 
by the ubiquitous NHE1, which are activated by growth factors, oncogenic transformation, 
hypoxia, and low intracellular pH. Normal cells, which lack mechanisms to adapt to 
extracellular acidosis, are unable to survive under these conditions, whereas the tumour 
population continues to proliferate [5]. Moreover, evidence show that both lactate and 
pyruvate regulate hypoxia- inducible gene expression, independently of hypoxia, by 
stimulating the accumulation of HIF-1α [18]. Extracellular acidity supports the process of 
invasion/metastasis, probably due to the pH-dependent activation of cathepsins and matrix 
metalloproteinases (MMP) that degrade extracellular matrix and basement membranes [5-6]. 
Also, HIF-1α causes loss of E-cadherin, which plays an important role in cell adhesion [11] and 
upregulation of hyaluronan and its receptor CD44, which  are  molecules  also involved  in  the  
process  of  cancer  invasion  and metastisation [19-20]. Additionally, extracellular acidification 
facilitates angiogenesis and tumour metastasis through upregulation of VEGF [21-22], a 
stimulator of angiogenic process that is also largely induced by HIF-1α [11]. This allows the 
creation of a vascular system within the tumour, thus enabling tumour cells to obtain the 
oxygen and nutrients they need to survive and multiply [23]. The activity of antitumour 
immune effectors such as cytotoxic T lymphocytes (CTLs) and natural killer cells can be 
inhibited by the acidic microenvironment of tumour cells, whereas inflammatory cells that 
participate in tumour progression can be attracted by this same microenvironment. Hypoxic 
and tumour perinecrotic areas are often enriched in tumour-associated macrophages which 
constitute a negative prognostic marker. These macrophages facilitate angiogenesis, tumour 
cell migration and have immunosuppressive effects [24]. Thus, extracellular acidification exerts 
a suppressive effect on cell proliferation, cytokine production and cytolytic activity of CTLs, by 
blocking the capacity of these cells to export intracellular lactate, through MCT1 [11, 24]. It 
was demonstrated that elevated levels of lactate correlate with poor patient prognosis, 
disease-free  and overall survival in human cervical cancers [25], head and neck cancer [26], 
high grade gliomas [27] and non-small-cell lung cancer [28]. This evidence points to lactate as 
enhancing the malignant phenotype of tumour cells. Indeed, high tumour lactate levels are 
associated with increasing incidence of metastases [25-26, 29], tumour recurrence, patient 
survival [25-26] and radioresistance [5] (Figure 6). These results reveal the high clinical 
importance of glucose metabolism, however, other metabolic pathways such as glutaminolysis 
and serinolysis can culminate in lactate production [30-31]. 
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Figure 6: Lactate efflux by MCTs induces malignant phenotype by targeting several pathways.  
MMP- matrix metalloproteinase; VEGF- vascular endothelial growth factor; ECM- extracellular matrix [17]. 
 
 
 
1.3. Monocarboxylate Transporters 
 
The monocarboxylate transporter family, also denoted as Solute Carrier Family 16 (SLC16), 
comprises 14 related proteins, identified through sequence homology [32-34] (Figure 7). It has 
been demonstrated that the integral membrane transport proteins MCT1-4, facilitates the 
diffusion of endogenous monocarboxylates, such as pyruvate, lactate and ketone bodies 
(acetoacetate-β -hydroxy-butyrate and acetate), across the plasma membrane [32, 34-36]. 
These substrates are cotransported with protons in an equimolar manner by a symport 
mechanism [32, 35]. 
During glycolysis two molecules of lactate are produced for each glucose molecule 
consumed, which must be transported out of the cell to maintain high rates of glycolysis[36]. 
Lactate efflux is especially important for most tumour cells, red and white blood cells, and 
tissues like skeletal muscle [32]. If efflux of lactate from these cells does not occur, intracellular 
concentrations will increase and the pH of the cytosol will decrease. This leads to inhibition of 
Phospho-fructokinase-1 and consequently to glycolysis [34, 36]. In contrast, other tissues, like 
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brain, heart and red skeletal muscle need rapid lactate uptake, where it is oxidized and used as 
a respiratory fuel [32, 36]. The same happens for tissues such as the liver, which, through the 
operation of the Cori cycle, use lactate as its central gluconeogenic substrate[36]. Transport of 
lactate and other monocarboxylic acids both into and out of cells play a central role in cellular 
function. 
MCTs are widely distributed throughout various mammalian tissues (Table 1) and cell 
types. Numerous drugs contain a carboxyl group in their chemical structure making these 
compounds potential substrates for MCTs [35-36]. Consequently, these transporters are 
possible gateways to drug delivery and the molecular structure, function, and regulation of 
expression of MCTs are important features in drug delivery and design. [35] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Phylogram of MCT protein sequences performed with ClustalW [37]. 
 
 
1.3.1. Structure of MCT family 
 
Structure prediction of MCTs  showed 10 -12 [38] [34-35] alpha-helical transmembrane 
domains  (12 TMDs for MCT1-4, MCT7 and MCT8 [36])  with the N- and C-terminal located in 
the cytoplasm [34, 38]. Topological prediction has been experimentally confirmed only for 
MCT1 in erythrocytes (Figure 8) [36, 38], nevertheless, analysis of the deduced amino acid 
sequences of the other MCT orthologs reveals a similar predicted topology [38]. 
The TMDs are highly conserved among isoforms with the main regions of variation 
observed in the hydrophilic regions [36]: N-and C-terminus  and the large intracellular loop 
between TMDs 6 and 7- hydrophilic regions [33-35, 38]. This variability is common in 
Chapter 1  Introduction 
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
13 
transporters with 12 TMDs [34] and this is directly related to substrate specificity, through the 
C-terminal domains, or regulation of transport activity, membrane insertion and correct 
structure maintenance, mediate by N-terminal domains [36].  
Also, mutations in some highly conserved residues, such as the arginine residue in TM8 in 
all MCTs from higher eukaryotes, except MCT5, affect substrate affinity.  Site directed 
mutagenesis of this residue (Arg313 of human MCT1), greatly reduces the affinity of MCT1 for 
lactate [36]. 
 
Figure 8: The predicted topology of MCT family members [36]. 
 
 
 
1.3.2. Regulation of MCT family 
 
Regulation of MCTs seems to occur via transcriptional and post-transcriptional 
mechanisms, and these regulatory pathways appear to be age- and tissue-dependent [34]. For 
example, there is evidence of changes in MCT isoform expression during development in 
tissues like heart, muscle [39], the inner ear [40] and brain [41], whilst the transition to 
malignancy in the colon [42] and brain [43] is accompanied by changes in the level of MCT1 
expression. Hypoxia conditions are also associated with altered expression of MCTs, in which 
HIF-1α is a key player. Some studies suggest that MCT4 expression is associated with hypoxic 
conditions and promoter regulation by HIF-1α [44-46], leading to an increase in this MCT 
isoform [47]. However, some controversy remains on MCT1 regulation by hypoxia, since 
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induction and repression was shown in different studies [3, 44-47]. A recent study provide 
additional evidence on MCT regulation by hypoxia in breast carcinomas, in which MCT1 was 
associated with hypoxia markers (CAIX and GLUT1) while MCT4 was not [48]. 
Post-transcriptional regulation at the level of translation was observed for MCT1 at  the 5´- 
and 3´-UTR level, with which initiation factors and regulatory factors interact to enhance or 
repress translation [38]. Also, it was described that miR-124, a microRNA in the mammalian 
nervous system, regulates MCT1 expression [49]. 
In order to facilitate the appropriate expression of some MCTs, such as MCT1, MCT2 and 
MCT4, association with ancillary proteins is needed (e.g. CD147, gp70) [50] which can be 
involved in cellular localization [51] or protein-protein interactions [52]. However, the role of 
these accessory proteins in transporter function is not yet completely understood [51]. 
MCT glycosylation does not seem to be required for its function and there are no 
experimental data to support regulation of any MCT isoform by phosphorylation [38]. 
Furthermore, hormonal regulation has been described for MCTs, as well as regulation by 
insulin-like growth factor receptor type I  which up-regulates MCT1 [53]. It was also shown that 
thyroid-stimulating hormone and somatostatin increase both MCT1 and CD147 expression [54-
55]. Noradrenaline was reported as an inducer of MCT2 in mouse neurons, while 
triiodothryonine induce MCT4 in rat skeletal muscle [56-57]. 
 
 
1.3.3. Different MCT isoforms 
 
MCTs 1-4 were the first characterized members of the SLC16 family and have been shown 
to transport monocarboxylates, important metabolic compounds [32-33]. 
MCTs 5–7, 9 and 11–14 are described as orphan transporters whose substrates are as yet 
unknown [33-34]. Table 1 details the human tissue distribution of these MCT isoforms. 
However, these MCT members have not been functional expressed nor characterized [36] and 
their functional role has yet to be completed. 
MCT8 and MCT10 demonstrate a wide tissue distribution (Table 1) and its functional 
characterization revealed that monocarboxylates, including lactate and pyruvate, were not 
substrates for these transporters. MCT8 is a thyroid hormone transporter, which actively 
transport the thyroid hormones- triiodothyronine (T3) and thyroxine (T4), while MCT10 
transport aromatic aminoacids. In contrast to other members of MCT family, both isoforms 
have been demonstrated to transport their respective substrates in a proton- and Na+-
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independent manner. One structural characteristic feature of both MCT8 and MCT10 is the 
presence of a peptide sequence which is rich in proline, glutamic acid, serine, and threonine 
(PEST motif) in the N-terminus of each protein, indicative of rapid protein degradation [34-36]. 
Below, the best characterized subtypes of MCTs in human tissue, the proton-coupled 
MCT1-4, will be address. 
 
1.3.3.1. MCT1 
 
MCT1 is the most well-studied and functionally characterized member of the MCT family 
[32]. MCT1 was first identified in Chinese hamster ovary (CHO) cells and subsequently, human, 
rat and mouse homologues sequences were identified [32, 34]. 
It is the only monocarboxylate transporter expressed in human erythrocytes [58], which 
was first functionally characterized in this endogenous tissue [59] and later in exogenous 
expression systems, such as Xenopus laevis oocytes [60]. This protein is predicted to have 494 
amino acids, 12 alpha-helical transmembrane domains [35] and a molecular weight of ~54 kDa 
[32]. Tissue distribution of MCT1 is ubiquitous [34, 38] however, localization within specific 
tissues varies, such as the retinal pigment epithelium (RPE) where its expression is restricted to 
the apical membrane [34]. 
Transport kinetics have been carefully studied using lactate and have demonstrated that 
MCT1 functions as a proton-dependent co-transporter [34]. Lactate efflux and uptake occurs 
by ordered sequential binding of a proton followed by lactate binding by a symport mechanism 
(Figure 9). The complex is translocated across the membrane and lactate and proton are 
released sequentially [34, 38]. Translocation is also performed by exchange of one carboxylate 
for another [38].  
 
 
 
 
Figure 9: Schematic representation of MCT1 lactate transport with respective chaperone. 
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1.3.3.1.1. MCT1 substrates 
 
MCT1 transports a wide variety of monocarboxylates from two to five carbon atoms (short 
chain unbranched aliphatic monocarboxylates), such as acetate (Km 3.5 mM) and propionate 
(Km 1.5 mM) [34, 38]. However, a group of substrates with substitutions on C2 and C3 are 
preferred (amino and amido substitutions are not tolerated [33]), which include such 
important metabolites such as L-lactate (Km 3–5 mM), pyruvate (Km 0.7 mM), acetoacetate (Km 
4–6 mM), and β-hydroxybutyrate (Km 10–12 mM) [32, 38]. Transport of lactate is 
stereoselective, with Km for D-lactate 10 times higher than L-lactate [61]. Monocarboxylates 
like methanoate are poor substrates, while bicarbonate, dicarboxylates, tricarboxylates and 
sulphonates are not transported by MCT1 [33, 38]. 
Hydrophilic segments of the transporter can also affect its function and stability, as it has 
been demonstrated for rat MCT1. Mutational analysis of conserved amino acids located in the 
loop between TMD 4 and 5 showed that mutation of lysine 142 to glutamine resulted in an 
increase in Km for L-lactate from 5mM to 12mM and a decreased stereoselectivity of the 
transporter, indicating the involvement of this residue in substrate recognition. In the same 
loop, mutation of arginine 143 to glutamine had a more drastic effect eliminating MCT1 
transport activity [62]. The spontaneous mutation of arginine 306 to threonine in TMD 8 also 
resulted in strongly reduced overall MCT1 transport [32]. 
 
 
 
1.3.3.1.2. MCT1 regulation 
 
MCT1 expression is regulated by transcriptional, post-transcriptional and post-translational 
mechanisms and this appears to occur in a tissue-specific manner [34].  
In colonic epithelium, exposure to butyrate results in a concentration- and time-dependent 
increase in MCT1 mRNA, protein expression and a corresponding increase in butyrate 
transport, point to transcriptional and post-transcriptional regulation [63].  
High concentrations of lactate have also been demonstrated to increase MCT1 mRNA and 
protein levels in L6 myoblast cells [9]. In contrast, treatment with testosterone resulted in an 
increase of skeletal muscle MCT1 protein expression and lactate transport in the absence of 
mRNA changes suggesting the importance of post-transcriptional regulation [64]. In addition, 
increased MCT1 expression and activity have been reported in human neuroblastoma and 
melanoma cell lines resulting from low extracellular pH [65-66]. 
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MCT1 is further regulated by its association with the cell surface glycoprotein CD147 (also 
known as OX-47, EMMPRIN, HT7 or basigin) which has a single transmembrane domain with 
the short C-terminus located in the cytosol and an immunoglobulin-like extracellular segment 
[50, 67]. Topology studies suggest that one MCT1 molecule interacts with a single CD147 
molecule with subsequent dimerization with another MCT1/CD147 pair [67]. The initial 
association of CD147 and MCT1 is required for the translocation of MCT1 to the plasma 
membrane [50]. Furthermore, studies indicate that covalent modification of CD147 results in 
inhibition of lactate transport as it is shown with p-chloromercuribenzene sulphonate 
(pCMBS)-mediated inhibition of transport (48, 50). In addition to MCT1, CD147 functions as an 
ancillary protein for MCT4 but not MCT2 [34]. 
Six transcripts have been described for MCT1 gene, 4 with protein production and 2 with no 
translational production [68]. Glycosylation was not found in mouse and hamster MCT1 [32]. 
The MCT1 5′- and 3′- UTR present a variety of transcription factor binding sites which appear 
to be involved in multiple regulation pathways [34]. 
MCT1 inhibition and silencing in neuroblastoma and glioma cell lines resulted in decreased 
intracellular pH, leading to apoptotic cell death, suggesting that MCT1 may represent a novel 
chemotherapeutic target [34]. 
 
 
 
 
1.3.3.2. MCT2 
 
In humans, expression of MCT2 is more restricted than MCT1, with the high levels of 
expression in testis [33-34] and moderate to low expression in spleen, heart, kidney, pancreas, 
skeletal muscle, brain, and leukocyte [33]. Additionally, species differences have been 
observed in both its amino acid sequence and tissue distribution [34, 38]. Higher levels of 
MCT2 in the liver were observed in rodents, whereas MCT2 protein expression is not 
detectable in human liver. MCT2 expression in brain and cellular localization also appears to be 
highly species dependent [34]. Where MCT2 is expressed together with MCT1 its exact location 
within the tissue is different, suggesting a unique functional role [38]. Lin and colleagues, 
verified that MCT2 is expressed in a number of human cancer cell lines but not in the 
respective native tissue, suggesting a specific role for this MCT isoform in cancer cell 
metabolism [69].  
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1.3.3.2.1. MCT2 Substrates 
 
MCT2 catalyses the proton-linked transport of a variety of monocarboxylates such as 
MCT1. However, substrate affinities was demonstrated to be higher for both pyruvate 
transporter (Km=25 μM)[32, 34-35] and L-lactate (Km= 1mM) for human MCT2 expressed in 
Xenopus oocytes [32]. Moreover, MCT2 had a higher affinity for ketone bodies and β-
hydroxybutyrate [33, 36]. The main role of MCT2 is the uptake of monocarboxylates into the 
cells in normal cell metabolism [70]. 
 
 
1.3.3.2.2. MCT2 Regulation 
 
MCT2 splice variants have been detected in both rodents and humans and transcriptional 
and post- transcriptional regulation seems to be species and tissue-dependent [71]. 
Similar to MCT1, MCT2 requires an accessory protein for correctly expression at the cell 
surface.  Nevertheless, MCT2 does not interact with CD147 but requires a related protein, 
namely gp70 or EMBIGIN [34, 38].  
 
 
 
1.3.3.3. MCT3 
 
MCT3 is exclusively located in the basolateral membranes of the RPE and choroid plexus 
epithelium (CPE) [32-33, 35]. This transporter was previously found in the chicken retina and 
orthologs in rat, mouse, and human have been identified [33]. 
 
1.3.3.3.1. MCT3 Substrates and Regulation 
 
Chicken MCT3 has a Km value similar to MCT1, ~6 mM and ~1 mM for L-lactate and 
pyruvate, respectively [32-33] 
Wilson and colleagues [72], sequenced chicken MCT3 gene and showed that it contains 
two alternative exons- 1a and 1b in the 5’-UTR that give rise to mature mRNA transcripts of 
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2.45 kb and 2.2 kb respectively [36, 72]. The 2.2 kb form (MCT3b) is found early in embryonic 
development, but it´s replaced by the 2.45 kb form (MCT3a) later in development and in the 
adult chicken RPE [35, 72]. These transcripts are expressed at different times during chicken 
eye development, suggest the existence of an important regulatory mechanism for temporal 
expression through the control of diverse promoters [36].  
It has been reported in CD147-null (Bsg-/-) mice a reduced expression of MCT3 in RPE 
which suggested that CD147 is also the accessory protein for this MCT isoform [73]. 
Further information on human MCT3 substrates or inhibitors is not published neither there 
is detailed information about the regulation of MCT3, only that no splice variants of human 
MCT3 are known [35, 38]. 
 
1.3.3.4. MCT4 
 
MCT4 is strongly expressed in glycolytic tissues such as white skeletal muscle fibres, 
astrocytes, white blood cells, chondrocytes and some mammalian cell lines [33-34, 38]. This 
isoform probably has a particular importance in tissues that rely on high levels of glycolysis and 
thus have a need to export lactic acid [34, 38]. The physiological function of MCT4 in lactate 
efflux (Figure 10) is further supported by its high expression in the placenta where it is involved 
in the transfer of lactate into the maternal circulation [74]. 
 
   Figure 10: Schematic representation of MCT4 lactate transport with respective chaperone. 
 
 
1.3.3.4.1. MCT4 Substrates  
 
The main distinction in the substrate specificity of MCT1 and MCT4, consists on how their 
substrate affinities with MCT4 exhibiting a much lower affinity for a wider range of 
monocarboxylates [34, 38]. Characterization of MCT4 transport in Xenopus oocytes revealed 
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values of Km and Ki some 5–10 times higher than MCT1 [33], with Km~28 mM for L-lactate and 
Km~150 mM for pyruvate [34, 38].  
 
1.3.3.4.2. MCT4 regulation 
 
Proper expression of MCT4 at the cell surface is dependent on CD147, which may also be 
important in determining its activity and location [34]. MCT4 and CD147 expression was 
induced in MDA-MB-231 cells (a highly invasive breast cancer cell line) supporting the 
metabolic switch to highly glycolytic cells in metastasis and the corresponding increase in 
lactate efflux [75]. 
MCT4 appears to be alternatively spliced since eight different mRNAs coding for rat MCT4 
were identified by 5’-RACE-PCR. Analysis of MCT4 mRNA expression in different rat tissues by 
RT-PCR indicates a tissue-specific expression pattern of the variants [35]. 
 
 
 
1.3.4. MCTs Inhibitors 
 
A great number of MCT1 inhibitors are known and can be divided into three categories: 
 Bulky or aromatic monocarboxylates which act as competitive inhibitors, including 2-
oxo-4-methylpentanoate, phenyl-pyruvate and derivatives of α-cyanocinnamate such 
as α-cyano-4-hydroxycinnamate (CHC). These are the most potent inhibitors of this 
class with Ki of 64 µM for MCT1 [58].  
 Amphiphilic compounds with divergent structures including bioflavonoids (quercetin 
and phloretin) and anion exchanger (AE) inhibitors such as 5-nitro-2-(3-phenyl-
propylamino)-benzoate (NPPB) and niflumic acid [33, 38]. These are potent inhibitors 
(K0.5 1–10µM) although they also inhibit AE isoform 1, and other membrane transport 
processes [38]. 
 Stilbene-derived compounds as 4,40-diisothiocyanostilbene-2,20-disulphonate (DIDS) 
and 4,40-dibenzamidostilbene-2,20-disulphonate (DBDS), act as reversible inhibitors of 
MCT1 in erythrocytes, although with much lower affinity than for AE1. Prolonged 
incubation with DIDS irreversibly inhibits MCT1, reflecting covalent modification of the 
transport [76]. MCT1 is also inhibited irreversibly by thiol reagents such as pCMBS and 
amino reagents (e.g. pyridoxal phosphate and phenyl-glyoxal) [36]. Interestingly it has 
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been shown that pCMBS inhibition is not on MCT1 directly, but on the accessory 
protein CD147 [33]. 
 
MCT2 is more sensitive to inhibition by CHC, DBDS and DIDS inhibitors than MCT1, but is 
insensitive to pCMBS [32-34, 36, 38]. It is possible that this difference in inhibitor insensitivity 
results from the different accessory proteins requirement of MCT1 and MCT2 [33-34]. 
However, in opposition to MCT1, MCT3 is insensitive to inhibition by CHC, pCMBS and 
phloretin [32-33]. 
MCT4 exhibits a much lower affinity for a wider range of inhibitors than MCT1 [34, 38] In 
contrast to other MCTs, lactate transport via MCT4 is inhibited by a range of statin drugs [77]. 
None of these inhibitors is specific for one MCT isoform, so some caution is necessary 
when using them to investigate the role of this MCT in cellular function. For example CHC that 
also inhibits other transporters of monocarboxylates, like mitochondrial pyruvate transporter 
with a Ki of <5 µM, as well as the AE1 [36, 58]. 
 
 
1.3.4.1. Quercetin as inhibitor of MCT activity 
 
Quercetin (3,5,7,3’,4’-pentahydroxylflavone), a major representative of the flavonoids, is 
present in fruit and vegetables and have attracted much attention as a potential anti-
carcinogen  compound [78-79]. Some studies reported that Quercetin have many beneficial 
biological activities including antioxidant, anti-inflammatory, antiallergic, antiviral, and 
anticarcinogenic proprieties [78-80]. Epidemiological studies suggesting that a high intake of 
fruit and vegetables is associated with a low risk of cancer development, including colon, 
breast, lung, laryngeal, pancreatic, bladder, stomach, esophageal, and oral cancers [80]. In 
order to understand this antitumour proprieties, several studies have been conducted and it 
have demonstrated that Quercetin inhibit the proliferation of a wide range of cancers such as 
prostate, cervical, lung, breast, and colon [81-82]. Several Quercetin targets and/or 
mechanisms involved in antitumour proprieties have been reported:   
a) Activation of pro-apoptotic proteins (Bax), release of cytochrome c, and up-
regulation of caspase- 3, -8, -9 to induce apoptosis [82-84]. 
b) Modulation of insulin-like growth factor binding protein-3 (IGFBP-3) in human 
prostate cancer cells [85]. 
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c) Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular regulated 
kinase (ERK) [86]pathways in human hepatoma HepG2 cells [84-85]. 
d) Inhibition of cell cycle progression from G1 to S phase, probably by p21 
accumulation [79].  
e) Inhibition of efflux transporters, including ABCB1 (P-glycoprotein), ABCC1/2 
(MRP1/2) and ABCG2/BCRP (breast cancer resistance protein) increasing 
intracellular concentration of anti-cancer drugs, reversing multidrug resistance 
[78, 87]. 
f) Down-regulation of β-catenin signaling pathway [87].  
g) Modulation of factor nuclear kappa B (NFκB) [80] and AMPK/COX-2 pathway in 
breast and colon cancer cells [86]. 
h) Reduction of epidermal growth factor receptor (EGFR) family (ErbB2 and ErbB3) 
expression in HT-29 colon cancer cells [88]. 
i) Reduction of pro-inflammatory cytokines and expression of inducible nitric oxide 
synthase (iNOS) [80]. 
j) Interaction with aryl hydrocarbon receptor (AhR) and androgen receptor [87]. 
k) Inhibition of migration in colon cancer cells [80], invasion inhibition in melanoma 
and prostate cancers [89-90] and inhibition of MMP-9 expression in glioma cells 
[91]. 
l) Suppression of tube formation in human umbilical vascular endothelial cells in 
response to antiangiogenic activity [92].   
Importantly, it was shown that Quercetin also inhibits the membrane transport of lactate in 
rat tumour cells [93] and red blood cells [59]. More recently, a study aiming to clarify the role 
of flavonoids in the modulation of MCT1-mediated transport of γ-Hydroxybutyrate 
demonstrated that Quercetin is an effective inhibitor of MCT1 [78]. Importantly, Quercetin is 
not transported by MCTs, whereas its metabolites are [94].   
 
 
1.3.4.2. Lonidamine as inhibitor of MCT activity 
 
Lonidamine (1-[(2,4-Dichlorophenyl)methyl]-1H-inda-zole-3-carboxylic acid), an 
experimental drug, was originally  developed as a non-hormonal male contraceptive agent[95], 
but it was more recently described as a pro-apoptotic and an anti-glycolytic drug [96-97]. The 
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efficacy of this drug against a large range of solid tumours has been observed. Some studies 
demonstrated that Lonidamine inhibits aerobic glycolysis via direct inhibition of Hexokinase II 
activity and inhibits oxygen consumption in Ehrlich ascites tumour cells [97-99]. However, the 
effects of Lonidamine were also attributed to the inhibition of lactate transport and its 
intracellular accumulation in neoplastic cells [98, 100-101]. Recently, Fang and colleagues 
suggested Lonidamine as an inhibitor of MCT isoforms 1 and 4 since  treatment of 
neuroblastoma cells with Lonidamine induced a decrease in intracellular pH [65]. Also, the 
capacity to modify the permeability of plasma and mitochondrial membranes was reported, 
enabling the increase in drug uptake, reversing drug resistance and activating the apoptotic 
pathway [102-103]. In cellular studies, Lonidamine has been efficient in the treatment of 
adriamycin resistant breast cancer cells [104], nitrosourea resistant glioblastoma cells (LB9) 
[105-106] and doxorubicin resistant hepatocarcinoma (HepG2) cells [107]. A recent study also 
demonstrated that Lonidamine inhibits endothelial cell functions involved in angiogenesis and 
vessel formation [103]. 
Phase II and phase III trials demonstrated the efficacy of Lonidamine on metastatic breast 
cancer [108-109], advanced ovarian cancer [110-111], inoperable non small lung carcinoma 
[112]and glioblastoma multiforme [113]. Recently, benign prostatic hyperplasia clinical trials 
progressed to phase II, however they were stopped in 2006 due to the occurrence of elevated 
liver enzymes in several patients [114-115]. Nevertheless, Pronzato and colleagues reported 
that toxicity of Lonidamine in women with breast cancer, mainly myalgia and asthenia, would 
be reversible if the dose was reduced [109]. The combination of Lonidamine with 
chemotherapy and/or radio therapy in the treatment of solid tumours is promising, however 
more studies are needed [102].  
 
 
1.3.4.3. Isoform specific MCT Inhibitors   
 
 As previously mentioned, none of the MCT classical inhibitors (e.g. CHC, DIDS, Quercetin 
and Lonidamine) is either MCT specific or MCT isoform specific. Consequently, the functional 
role of MCTs should be studied using specific inhibitors. Recently, AstraZeneca developed a 
new set of immunomodulatory compounds as potent and selective inhibitors of MCT1 in 
activated human and rat T cells [116-117].  
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 Table 1: Members of Monocarboxylate Transporter Family, adapted from [38]. 
 
Protein 
name 
Principal 
Substracts 
Tissue distribution 
Human 
gene name 
Human 
gene locus 
NCBI 
Reference 
Sequence 
MCT1 
Lactate, 
pyruvate, 
ketone bodies 
Ubiquitous SLC16A1 1p12 NP_001159968.1 
MCT2 
Lactate, 
pyruvate, 
ketone bodies 
Kidney, brain SLC16A7 12q13 NP_004722.2 
MCT3 Lactate RPE, CPE SLC16A8 
22q12.3-
q13.2 
NP_037488.2 
MCT4 
Lactate, 
pyruvate, 
ketone bodies 
Skeletal muscle, 
condrocytes, 
leucocytes, testis, 
lung, placenta, heart 
SLC16A3 17q25 NP_001035887.1 
MCT5 ? 
Brain, mucle, liver, 
kidney, lung, ovary, 
placenta, heart 
SLC16A4 1p13.3 NP_004687.1 
MCT6 ? 
Kidney, muscle, 
brain, heart, 
pancreas, prostate, 
lung, placenta 
SLC16A5 17q25.1 NP_004686.1 
MCT7 ? 
Brain, pancreas, 
muscle 
SLC16A6 17q24.2 NP_001167637.1 
MCT8 T3, T4 
Liver, heart, brain, 
thymus, intestine, 
ovary, prostate, 
pancreas, placenta 
SLC16A2 Xq13.2 NP_006508.1 
MCT9 
? 
Endometrium, testis, 
ovary, breast, brain, 
kidney, adrenal, RPE 
SLC16A9 10q21.2 NP_919274.1 
MCT10 
(TAT1) 
Aromatic 
amino acids 
Kidney, intestine, 
muscle, placenta, 
heart 
SLC16A10 6q21-q22 NP_061063.2 
MCT11 
? 
Skin, lung, ovary, 
breast, pancreas, 
RPE, CPE 
SLC16A11 17p13.2 NP_699188.1 
MCT12 ? Kidney SLC16A12 10q23.31 NP_998771.3 
MCT13 ? 
Breast, bone marrow 
stem cells 
SLC16A13 17p13.1 NP_963860.1 
MCT14 
? 
Brain, heart, ovary, 
breast, lung, 
pancreas, RPE, CPE 
SLC16A14 2q36.3 
NP_689740.2 
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1.4. Role of MCTs in cancer 
 
As described previously, high levels of lactate production is a commonly observed feature 
of tumour cells. MCTs play a vital role in intracellular pH homeostasis, exporting the 
accumulating lactate [5, 35].  
There is evidence for the upregulation of MCTs in tumours, such as soft tissue sarcoma 
[118], high-grade gliomas [43], colorectal carcinomas [119-120], neuroblastomas [65], lung 
cancer [121], cervical cancer [122] and breast carcinoma [123] . Also, human melanoma cells 
have been shown to have increased levels of activity of MCT1 and MCT4 when exposed to low 
extracellular pH, suggesting either an increase in protein levels and/or an increase in activity 
[35].  In neuroblastoma, gene profiling microarray studies allowed the molecular 
characterization of different tumour phenotypes. MCT1 was the only member found to be 
differentially expressed, leading to the hypothesis that expression of MCT1 could be associated 
with higher malignancy [65]. 
In cervical cancer, as well as in most of tumours, lactate is associated with poor prognosis 
[25, 124], in which MCTs have an important role. In a recent study by Pinheiro and colleagues, 
a significant increase in MCT expression from pre-invasive to invasive squamous lesions and 
from normal glandular epithelium to adenocarcinomas was found [122]. The same group, in 
another study, observed a preferential expression of MCT4 in intestinal-type gastric 
carcinoma, although with a decrease in MCT4 expression from normal to malignant gastric 
mucosa [125]. 
In contrast to MCT1 up-regulation providing an adaptive benefit to cell growth of some 
tumours, down-regulation of this transporter is observed in colonic carcinomas. MCT1 is 
expressed in normal colonic epithelium to facilitate the transport of butyrate, the primary 
energy source of these cells. The loss or silencing of MCT1 reduced butyrate uptake and 
increasing glucose transporter expression may reflect energy substrate requirements of 
tumours during transition from normality to malignancy [17, 35]. 
However, an opposite finding on MCT expression in colon tissue indicates that there is an 
increase in MCT1, MCT2 and MCT4 in colorectal carcinoma compared to normal colonic 
epithelium. The most notable findings in this study were the significant increase of MCT1 and 
MCT4 expression in cancer cell plasma membrane [119-120].  
In lung cancer, MCT1, MCT2 and MCT4 expression is found among the plasma membrane 
of tumour cells, with very weak expression in cytoplasm, and no MCT expression in normal 
lung tissue [121]. In breast cancer, where there are a very limited number of studies, a 
previous report suggested a possible silencing of MCT1 expression in these tumours [126].  
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However, in a recent study, a significant increase in MCT1 expression was described, especially 
in a subset of aggressive breast carcinomas (basal-like) when compared with normal breast 
tissue. In this study, MCT1 and CD147, alone or in co-expression, were also associated with 
estrogen receptor (ER) and progesterone receptor (PR) absence, high histological grade 
tumours, and tumours expressing cytokeratin 5 and 14, vimentin and Ki67, pointing a role of 
MCT1 in breast cancer aggressiveness [123]. Another study of the same group, reported the 
association of MCT1 in breast cancer, especially in the aggressive basal-like subtype, with 
GLUT1 and CAIX [48], which are associated with shorter disease-free survival [16, 119-121]. 
Thus, MCTs can constitute attractive targets for cancer therapy, in which lactate 
transporter inhibitors may provide new effective approaches.  
 
 
1.4.1. MCTs inhibition in tumour cells 
 
Inhibition of MCTs activity and/or expression will have a direct effect on monocarboxylate 
transport and pH. As a result, it has been demonstrated that MCT1 inhibition decreases 
intracellular pH, resulting in cell death [3, 65-66, 88]. 
Additionally, MCT inhibition may eliminate tumour cells by another mechanism. Hypoxic 
tumour cells depend on glucose and glycolysis to produce energy, causing the extracellular 
environment to become more acidic by lactate production. By contrast, aerobic tumour cells 
import this lactate, mediated by MCT1 located at the cell plasma membrane and oxidize it to 
produce energy. Glucose freely diffuses through the aerobic tumour cell reaching hypoxic 
tumour cells, conferring a survival advantage to the hypoxic tumour cells [3, 17]. This 
metabolic symbiosis can be disrupted by MCT1 inhibition. Upon MCT1 inhibition, aerobic 
tumour cells switch from lactate oxidation to glycolysis, thereby preventing adequate glucose 
delivery to glycolytic cells (hypoxic cells), which die from glucose starvation (Figure 11). MCT1 
inhibition is thus a potent antitumour strategy that indirectly eradicates hypoxic/glycolytic 
tumour cells [3]. Also, inhibition of MCTs may suppress cell migration, as demonstrated in 
MDA-MB-231 cells where silencing of MCT4 via small interfering RNA  (siRNA) reduced 
transwell migration by as much as 85% [75]. So, inhibition of MCT expression could reduce cell 
proliferation and migration, increase cell death through intracellular acidification or through 
hypoxic cell starvation [17]. Targeting MCT activity would not only induce apoptosis due to 
cellular acidosis, but would also lead to reduction in tumour angiogenesis, invasion, and 
metastasis [17, 119].  
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Figure 11: Model for therapeutic targeting of lactate-based metabolic symbiosis in tumours.  
GLUT- glucose transporter, MCT- monocarboxylate transporter [3]. 
 
Therefore, MCTs seem to constitute an excellent target for cancer therapy. However, 
when considering MCTs as targets for therapy, it is crucial to consider the possible toxicity to 
normal tissues [3]. These molecules have the potential to alter metabolism, inflammatory 
response, intracellular pH, and angiogenic response on a large spectrum. So, in order to 
prevent toxic whole-body effects local delivery of inhibitor/drug would be desirable. Systemic 
delivery of MCT inhibitors, and specifically MCT1, could affect almost every organ of the body, 
with most drastic effects on cardiac and skeletal muscle. As MCT1 is indispensible to lactate 
shuttle in skeletal muscle, possible side effects will include muscle fatigue and intolerance to 
moderate-high physical exercise due to extracellular acidification and impossibility to perform 
lactate uptake by oxidative muscle fibers. In colonic epithelium, MCT1 is responsible for 
butyrate transport, and inhibition of this transporter may inhibit cell proliferation and correct 
differentiation [17]. While MCT1 specific inhibition is being explored for immunosupression 
due to T cell activation by MCT1, in the cancer context, immunosupression against cancer cells 
is a true possibility. However, treatment with Lonidamine has moderate side-effects like 
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myalgia, asthenia, testicular pain, and gastrointestinal discomfort, with no serious organ 
toxicity or myelosupression [102].  
Much attention has been given to the tumour metabolic manipulation, in the context of 
cancer therapeutic approaches. Several drugs targeting metabolic pathways are currently in 
clinical trials. MCTs are not yet included in this list of metabolic targets for cancer therapy, 
however, targeting tumour acidification may have more than one benefit: the inhibition of 
glycolysis and in long term inhibition of tumour cell invasion. The glycolitic enzymes, such 
Hexokinase, Pyruvate Dehydrogenase Kinase 1, and Lactate Dehydrogenase  A; Sodium-
Hydrogen Exchangers, and the hypoxic associated protein Carbonic Anhydrase IX are other 
attractive candidates for targeting cancer therapy (Figure 12) [127].  
 
 
Figure 12: Actual and future therapeutic targets (dashed lines) of tumour metabolism by targeting 
metabolic enzymes. 5-FU, 5-fluorouracil; αKG, α-ketoglutarate; ACLY, ATP citrate lyase; CA, carbonic anhydrase; 
CINN, α-cyano-4-hydroxycinnamate; DCA, dichloroacetate; FASN, fatty acid synthase; G6P, glucose-6-phosphate; 
Glut, glucose transporter; HK, hexokinase; IGF1, insulin-like growth factor 1; IGF1R, IGF1 receptor; LDH, lactate 
dehydrogenase;  Mal, malate; MCT, monocarboxylate transporter; NHE1, Sodium-Hydrogen Exchanger 1; OAA, 
oxaloacetate; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PEP, phosphoenol pyruvate; PK, 
pyruvate kinase; R5P, ribose 5-phosphate; TCA, tricarboxylic acid cycle [127]. 
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1.5. Breast cancer 
 
Apart from skin cancer, breast cancer remains the most commonly diagnosed cancer 
among women and it is the second leading cause of cancer-related death in the developed 
world. Breast cancer is characterized by its molecular and clinical heterogeneity, as it is no 
longer seen as a single disease but rather a multifaceted disease comprised of distinct 
biological subtypes with diverse natural history, presenting a varied spectrum of clinical, 
pathologic and molecular features with different prognostic and therapeutic implications 
[128]. 
The normal human breast consists of ductal epithelium and surrounding stroma. The 
stroma consists of more than 80% of the breast volume, and provides nutrition and structural 
support to the normal epithelium. Breast carcinoma is thought to derive from epithelial cells of 
the terminal duct-lobular unit. However, growing evidence indicates that the stroma may play 
an important role in cancer initiation and progression [129]. There are some risk factors that 
are also known to be liable for about 40% of all breast cancer cases: genetic/familial, 
reproductive/hormonal, lifestyle, and environmental factors. 
There are several clinically recognized types of breast cancer, with ductal carcinoma the 
most prevalent, followed by lobular carcinoma, inflammatory breast cancer, medullary 
carcinoma of the breast, and other less common forms [130].  
Breast cancer can also be classified  according to gene expression profiles into five major 
subtypes: luminal A (ER+ and/or PR+, Her2-), luminal B (ER+ and/or PR+, Her2+), HER2+ (ER-, PR-, 
Her2+), basal-like (ER-, PR-, Her2-) and normal-breast like tumours [128, 131]. These molecular 
subtypes have important prognostic implications and different predictive value [128, 131-132]. 
Basal-like breast carcinoma, ‘‘triple-negative phenotype’’ and HER2+ have a more aggressive 
clinical behaviour when compared to luminal and normal-like breast carcinomas [128, 131].  
 
 
 
1.5.1. Basal-like carcinoma subtype 
 
Approximately 15% of breast cancers are basal-like and are associated with poor relapse-
free and overall survival [131]. A recent population-based study has shown that this subtype is 
more prevalent in premenopausal African American women, which may contribute to the poor 
outcomes seen among these patients [133]. Basal-like breast carcinoma is commonly 
associated with, younger age at diagnosis, more advanced stage, higher grade, high mitotic 
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index and family history of breast cancer and breast cancer 1 gene (BRCA1) mutations. The risk 
of recurrence peak occurs within three years of diagnosis, and mortality rates are increased in 
five years after diagnosis. This subtype has therapeutic implications because patients do not 
have a specific molecular therapy [123], as they do not benefit from anti-estrogen hormonal 
therapies nor from trastuzumab (used for the adjuvant treatment of patients with Human 
Epidermal Growth Factor Receptor 2 positive -HER2+)[128, 131] entailing the search for new 
molecular targets in this aggressive group of tumours .  
 
 
 
1.6. Aims 
 
Some evidence points MCTs as potential targets for cancer therapy [17, 36] however, the 
role of these proteins in solid tumour development and survival remain unclear especially in 
breast cancer, where there is a very limited number of studies.  One the most recent study 
showed a significant gain in MCT1 plasma membrane expression and no significant alteration 
in MCT4 expression in tumours, when comparing to non-neoplastic tissue and importantly, 
MCT1 expression correlated with basal-like phenotype [123]. 
Considering that MCTs have been pointed several times as promising targets in cancer 
therapy, the main goal of this work is to give a clear understanding of MCT activity inhibition in 
breast cancer cells. Thus, total cellular biomass, metabolism, proliferation, death, migration 
and invasion will be evaluated upon inhibition of MCT activity by Quercetin and Lonidamine, in 
six breast cancer cell lines. Certainly, the major aim is to contribute to the exploitation of 
breast cancer MCT-based therapeutic approaches, especially in the basal-like subtype. 
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2.1. Cell lines and cell culture conditions 
 
The human breast cancer cell lines MDA-MB-468, MDA-MB-231, Hs578T and BT-20 (basal 
subtype), MCF-7/AZ (luminal subtype) and SkBr3 (Her2 + subtype), were obtained from ATCC 
(American Type Culture Collection) or from collections developed in the laboratories of Drs 
Elena Moisseva (Cancer Biomarkers and Prevention Group, Departments of Biochemistry and 
Cancer Studies, University of Leicester, UK), Marc Mareel (Laboratory of Experimental 
Cancerology, Ghent University Hospital, Belgium) and Eric Lam (Imperial College School of 
Medicine, Hammersmith Hospital, London, UK). All cell lines were cultured in Dulbecco`s 
modified Eagle medium, 4.5g/l glucose (DMEM, Invitrogen) supplemented with 10% heat-
inactivated Fetal Bovine Serum (FBS, Invitrogen) and 1% antibiotic solution (penicillin-
streptomycin, Invitrogen). Cells were grown in a humidified incubator at 37C and 5% CO2.  
To cultivate cells for any assay, sub-confluent cells were harvested by gently rinsing flasks 
with phosphate-buffer saline (PBS) and then detaching with  tripsin at 37C. Tripsin was 
inactivated by addition of DMEM 10% FBS and cells were collected and centrifuged 5 minutes 
at 900rpm. Cells were re-suspended in fresh medium and 10µl of cell suspension were 
collected, in which 20µl of Tripan Blue was added. Cells were counted in a Neubauer chamber 
for posterior density calculation. 
 
2.2. Protein expression assessment 
 
2.2.1. Preparation of paraffin cytoblocks 
 
All cell lines were grown on T75 flasks until confluence was reached. Cells were then 
trypsinized and centrifuged at 1000 rpm during 5 minutes. The supernatant was discarded and 
cell pellets were incubated with 2-3ml of formaldehyde 3.7% overnight for fixation. Pellets 
were re-centrifuged before being processed in an automatic tissue processor (TP1020, Leica) 
and included into paraffin blocks (block-forming unit, EG1140H, Leica).  
 
2.2.2. Immunocytochemistry 
 
Protein expression of MCT1, MCT4, CD147 and Hexokinase II in cell cytoblocks was 
evaluated by immunocytochemistry (ICC). Immunocytochemistry provides a direct method for 
identifying subcellular protein distribution. Immunological staining is accomplished with 
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specific antibodies that will recognize the target protein. The antibody-antigen interaction is 
then visualized using chromogenic detection, in which an enzyme conjugated to the antibody 
cleaves a substrate to produce a colour precipitate at the location of the protein.  
For ICC studies cytoblock sections (4μm) were deparaffinised and rehydrated, and 
submitted to the adequate antigen retrieval, followed by endogenous peroxidase activity 
inactivation (detailed immunoreaction information is given in Table 2). Slides were incubated 
with the respective blocking solution for 10 (LabVision kit) or 20 minutes (Vector kit) and then 
followed by incubation with the respective primary antibody (see Table 2). After rinsing in PBS, 
slides were incubated with the secondary biotinylated antibody for 10 or 30 minutes, and then 
with Streptavidin/Avidin Peroxidase solution for 10 minutes at room temperature or 
45minutes at 37C, depending on the detection system kit used (LabVision or Vector kit, 
respectively). Immunoreactivity was visualized with 3,3’-diamino-benzidine (DAB+ Substrate 
System, Dako) for 10 minutes, slides were counterstained with haematoxylin and permanently 
mounted (EntellanTM). Cells were evaluated for positive expression, distinguishing cytoplasmic 
from membrane expression.  
Table 2: Details of the immunocytochemical procedure used to visualise the different proteins. 
Protein 
Positive 
Control 
Antigen 
retrieval 
Peroxidase 
inactivation 
Detection system 
Primary Antibody 
Company 
(reference) 
Dilution 
and 
incubation 
time 
MCT1 Colon 
carcinoma 
Citrate buffer 
(10mM,pH=6) 
98C; 20 min 
0.3% H2O2 in 
methanol,  
30 min 
R.T.U. VECTASTAIN 
Elite ABC Kit 
(VECTOR 
laboratories) 
Chemicon  
(AB3538P) 
1:300, 
overnight, 
RT 
 
MCT4 Colon 
carcinoma 
Citrate buffer 
(10mM,pH=6) 
98C; 20 min 
3% H2O2 in 
methanol,  
30 min 
R.T.U. VECTASTAIN 
Elite ABC Kit 
(VECTOR 
laboratories) 
Santa Cruz 
Biotechnolgy 
(SC-50329) 
1:200, 
overnight, 
RT 
CD147 Colon 
carcinoma 
EDTA 
(1mM,pH=8) 
98C; 15 min 
3% H2O2 in 
methanol,  
10 min 
Ultravision 
Detection System 
Anti-polyvalent, 
HRP 
(Lab Vision 
Corporation) 
ZYMED 
(18-7344) 
1:500, 
2 hours, 
RT 
HKII Colon 
carcinoma 
EDTA buffer 
(10mM,pH=6) 
98C; 20 min 
3% H2O2 in 
methanol,  
10 min 
Ultravision 
Detection System 
Anti-polyvalent, 
HRP 
(Lab Vision 
Corporation) 
AbCam 
(ab104836) 
1:750, 
2 hours, 
RT 
RT – room temperature 
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2.3. Chemicals 
 
Quercetin (Q4951) was obtained from Sigma-Aldrich and was dissolved in 
dimethylsulfoxide (DMSO, Sigma-Aldrich) at the concentration of 80mM. The remaining stock 
solutions were obtained with further dilutions in DMSO (40mM, 20mM, 10mM, 4mM, 2mM) 
and stored at -20C until used. 
Lonidamine (L4900) (Sigma-Aldrich) was dissolved in DMSO at a concentration of 80mM 
and the remaining stock solutions were obtained with further dilutions in DMSO 
(60mM,40mM, 20mM, 10mM) and stored at -20C until used. 
Quercetin and Lonidamine working solutions were freshly prepared in culture medium 
without serum. DMSO concentration in the cell culture medium never exceeded 0.5%. All 
controls were performed by adding DMSO to the cell culture medium in the same 
concentration as for Quercetin and Lonidamine solutions  
 
2.4. IC50 estimation 
 
To determine the Quercetin and Lonidamine IC50
 value for the different breast cancer cell 
lines, cells were plated in 96-well plates, at a different density for each cell line: 10000 
cells/100µl (Hs578T), 13000 cells/100µl (MCF-7/AZ and BT20), 15000 cells/100µl (SkBr3 and 
MDA-MB-231) and 20000 cells/100µl (MDA-MB-468) per well. Cells were allowed to adhere 
overnight and then were treated with various compound concentrations. For the first 
Quercetin screening assay 20, 50, 100 and 200µM concentrations were used for 24, 48 and 
72h; in the following assays, after concentration and time adjustment, 10, 20, 50 and 100µM 
Quercetin concentrations were used for 48h. Lonidamine was used at concentrations of 100, 
200, 300 and 400µM for 24, 48 and 72h in the first screening assay; in the following assays, 
after concentration and time adjustment 50, 100, 200 and 300µM Lonidamine concentrations 
were used for 48h. The respective controls were performed with the adequated % of DMSO. 
The effect of both inhibitors was evaluated by the Sulforhodamine B assay (SRB, TOX-6, Sigma-
Aldrich). The Sulforhodamine B assay system is a method for monitoring in vitro cytotoxicity 
(measuring total biomass) by staining cellular proteins with Sulforhodamine B. After cell 
incubation with Quercetin or Lonidamine, culture medium was removed and cells were fixed 
with cold 10% Trichloroacetic Acid (TCA) for 1h at 4ºC. Plates were rinsed 3 times with water to 
remove TCA and then were air dried for 1- 2 hours. Cells were stained with 0.4% 
Sulforhodamine B solution during 20minutes and, at the end of the staining period, plates 
were again rinsed 3 times with 1% acetic acid until the unincorporated dye was removed. After 
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the plates were dried, the incorporated Sulforhodamine B was solubilized in a 10mM Tris Base 
Solution during 10minutes at room temperature. Spectrophotometric measurement of 
absorbance was performed at 490nm, using 690nm as background absorbance (Tecan 
infiniteM200). IC50 values were estimated from three independent experiments (at least), each 
one in triplicate, using the GraphPad Prism 5 software, applying a sigmoidal dose-response 
(variable slope) non-linear regression, after logarithmic transformation. 
 
 
2.5. Glycolytic metabolism assays 
 
Glycolytic metabolism was assessed in all cell lines by analyzing extracellular glucose and 
lactate concentrations, which allow to infer on glucose consumption and lactate production 
rates. The metabolic assays were performed with confluent cells, to minimize variations due to 
cell growth and size. Cells were seeded in 24-well plates at different densities: 
1.8x105cells/500µl for Hs578T and BT20, 2x105cells/500µl for MCF-7/AZ, 2.7x105cells/500µl for 
MDA-MB-231 and SkBr3 and 4.6x105cells/500µl for MDA-MD-468, per well. Cells were allowed 
to grow overnight to reach confluence and then, incubated with Quercetin (40µM for MDA-
MB-231 and Hs578T or 50µM for MDA-MB-468, BT20, MCF-7/AZ and SkBr3), Lonidamine 
(100µM for MDA-MB-468 or 125µM for MDA-MB-231, Hs578T, BT20, MCF-7/AZ and SkBr3) or 
DMSO for controls. Cell culture medium aliquots (30µl) was collected from the 24-well plates 
at different time points (4, 8, 12 and 24 hours), assuring confluences similar to the ones 
observed in the control. The aliquots were stored at -20C until glucose and lactate 
quantification. Experiments were conducted in triplicate and repeated at least three times and 
data was evaluated in GraphPad Prism 5 software. 
 
 
2.5.1. Extracellular Glucose Quantification 
 
Measurement of glucose levels were assessed by an enzymatic colorimetric kit (Cobas, 
Roche Applied Sciences), based on the enzymatic oxidation of glucose by glucose-oxidase 
(GOD) resulting in gluconolactone and hydrogen peroxide (H2O2). The resultant H2O2 is used for 
production of a colorimetric product by peroxidase (POD), suitable for spectrophotometric 
quantification. The color intensity of the red compound formed is directly proportional to the 
glucose concentration in the sample: 
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  In a 96-well plate, 100µl of working solution was mixed with 100µl of each sample (1:100 
dilution in PBS). Blank was performed by adding 100µl of 1X PBS to 100µl of working solution. 
The mixture was gently homogenized and incubated for 20 minutes at room temperature. The 
absorbance was read at 490nm in a microplate reader (Tecan infiniteM200). Calculation of 
glucose levels was based in a calibration curve based in a range of glucose solutions with 
different concentrations (0.5, 1, 2, 4, 6, 8, 10µg/l Glucose). 
 
 
 
2.5.2. Extracellular Lactate Quantification 
 
The extracellular lactate levels were assessed by an enzymatic colorimetric kit 
(SPINREACT), based on the production of a colorimetric compound. Lactate is oxidized by 
lactate oxidase (LO) to pyruvate and hydrogen peroxide (H2O2). H2O2 is then converted to a red 
quinone, catalyzed by peroxidase (POD). The intensity of the colour formed is proportional to 
the lactate concentration in the sample: 
 
 
In 96-well plates, 200µl of working reagent was added to 2µl of samples. Lactate calibration 
was performed by adding 2µl of lactate standard solution (10 mg/dl) with 200µl of working 
reagent and blank was performed with 200µl of working reagent. The mixture was 
homogenized, incubated for 10 minutes at room temperature and absorbance was read at 
490nm in a microplate reader (Tecan infiniteM200).  
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2.6. Cell proliferation assay 
 
DNA synthesis of by cells was measured by Cell Proliferation ELISA, BrdU (colorimetric) 
assay (Roche Applied Sciences). BrdU cell proliferation assay is a colorimetric immunoassay 
based on the measurement of 5-bromo-2´-deoxyuridine (BrdU) incorporation during DNA 
synthesis.  
MDA-MB-468, MDA-MB-231, Hs578T and MCF-7/AZ cells were plated in 96- well plates at 
a density of 17000, 13000, 9000 and 10000cells/100µl, respectively, and grown overnight at 
37°C in a 5% CO2 humidified atmosphere. Then, adherent cells were treated with Quercetin 
and Lonidamine at IC50 concentrations or DMSO (controls) for 24 and 48 hours. After 
incubation, cells were labeled by addition of 5µl/well BrdU labeling solution (final 
concentration: 20µM BrdU) and reincubated for 6 hours. During this time period, the 
pyrimidine analogue BrdU was incorporated in place of thymidine into the DNA of proliferating 
cells. After labeling, culture medium was removed, cells were fixed and DNA was denatured by 
incubation with 100µl of FixDenat solution during 30 minutes at room temperature. 
Denaturation of DNA is necessary for antibody conjugate binding to the incorporated BrdU. 
Then, the FixDenant was removed, and 100µl of Anti-BrdU-POD antibody was added and 
incubated for approximately 90 minutes at room temperature. The Anti-BrdU-POD antibody 
binds to the incorporated BrdU in the newly synthesized cellular DNA. The antibody conjugate 
was removed and wells were rinsed three times with 1X PBS. The immune complexes were 
detected by adding 100µl/well of Substrate solution and the plate was incubated at room 
temperature until color development was sufficient for photometric detection (5-10 minutes). 
Substrate reaction was stopped by adding 25µl of 1M H2SO4 to each well and gently mixed. The 
reaction product was quantified by measuring absorbance at 450nm (reference wavelength: 
690nm) in a microplate reader (Tecan infiniteM200). Blank was performed in each 
experimental time point, without cells, performing all steps described above. The developed 
color and thereby the absorbance values directly correlate to the number of proliferating cells 
in the respective cell cultures. The results of at least three independent experiments (in 
triplicate) were evaluated with GraphPad Prism 5 software. 
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2.7. Cell Death Assay 
 
 Apoptotic and necrotic cell populations, two distinct mechanisms of cell death, were 
analysed by Flow Citometry using simultaneous staining with both FITC Annexin-V (BD 
Biociences) and Propidium Iodide (PI) (Sigma-Aldrich). In the early phases of apoptosis, 
membrane asymmetry is lost and phosphatidylserine (PS) is translocated from the inner to the 
outer membrane. Annexin-V, a calcium-dependent phospholipid-binding protein, binds to the 
PS exposed on the surface of apoptotic cells. Propidium Iodide is a viability probe used to 
distinguish viable from non-viable cells. This probe is impermeable and do not enter in the 
normal cells, which present intact membrane, whereas the membranes of necrotic cells are 
permeable to it. 
Cells were seeded into T25 flasks (4ml) at a density of 1.6x106cells/ml (MDA-MB-468), 
1x106cells/ml (MDA-MB-231 and Hs578T) and 1.2x106cells/ml (MCF-7/AZ) and grown 
overnight at 37C, 5% CO2 atmosphere. Cells were treated with Quercetin and Lonidamine at 
the respective IC50 and DMSO (controls) for 48 hours. After incubation, the supernatant was 
collected and treated cells were trypsinized. Cell suspensions were centrifuged at 1000rpm for 
5 minutes, the supernatant was discarded and the pellet was washed with 1X PBS. Each pellet 
was ressuspended in 1ml of Binding Buffer (10mM Hepes pH 7.4, 140mM NaCl, 2.5mM CaCl2) 
and equal volume was distributed for several eppendorfs, for compensation of fluorochrome 
spectral overlap, centrifuged at 2000rpm for 5 min and stained according to Table 3.  
 
 Table 3: Details of cell death assay procedure by Flow Cytometry. 
 Cells were incubated with staining solution for 15 minutes at room temperature and cell 
populations were analyzed by flow cytometry (LSRII, BD Biosciences). The percentage of viable, 
apoptotic and necrotic cells resulting from three independent experiments was evaluated with 
the GraphPad Prism 5 software. 
 
 
No staining Annexin-V staining PI staining Annexin-V and PI 
staining 
Control Cells 
300µl Binding 
Buffer 
8 µl Annexin-V + 
300µl Binding 
Buffer 
30 µl PI + 300µl 
Binding Buffer 
8 µl Annexin-V + 30 
µl PI + 300µl Binding 
Buffer 
Treated Cells 
300µl Binding 
Buffer 
  
8 µl Annexin-V + 30 
µl PI + 300µl Binding 
Buffer 
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2.8. Protein extraction and Western Blot Assay to Caspase-3 and PARP 
analysis 
 
Protein expression levels were determined by Western blot analysis, a technique that 
involves the transfer of proteins that have been separated by gel electrophoresis onto a 
membrane, followed by immunological detection. In this assay cleaved caspase-3 and PARP 
(Poly (ADP-ribose) polymerase) were analyzed to confirm the type of cell death, in which 
caspase-3 is one of the key in apoptotic pathway, responsible for proteolytic cleavage of 
nuclear protein PARP.  
 
Cells (MDA-MB-468, MDA-MB-231, Hs578T and MCF-7/AZ) were grown in T25 flasks and, 
when 70-80% confluence was reached, cells were exposed to Quercetin and Lonidamine at the 
respective IC50 or DMSO (controls) for 48 hours. After treatment, cells were collected by 
scraping and briefly centrifuged at 2000rpm for 5 minutes, at 4C. The pellet was washed with 
1X PBS and after new centrifugation, was ressuspended in Lysis Buffer (50mM Tris pH 7.6-8, 
150mM NaCl, 5mM EDTA, 1mM Na3VO4, 10mM NaF, 1% NP-40, 1 % Triton-X100 and 1/7 
protease inhibitor cocktail (Roche Applied Sciences)) at 4C and incubated for 10 minutes on 
ice. Lysates were centrifuged at 13000 rpm for 15 minutes at 4C and the supernatants 
collected for protein concentration determination using DC Protein Assay Kit (BioRad). Twenty 
µg of total protein of each sample were separated on 10-15% polyacrylamide gel (120V for 90-
150 minutes) and transferred onto a nitrocellulose membrane (100V for 60 minutes). 
Membranes were blocked with 5% milk in 1X TBS/0.1% Tween20 for 50 minutes before 
overnight incubation with the specific primary antibodies at 4C (rabbit anti-PARP antibody, 1: 
1000 5% BSA, Cell Signaling (#5625); rabbit anti-caspase-3 antibody, 1: 1000 5% BSA, Cell 
Signaling (#9664); goat anti-Actin antibody, 1: 500 5% milk, Santa Cruz Biotechnology (sc-
1616)). After washing 3 x 10 minutes with TBS/0.1% Tween 20, blots were incubated for 1 hour 
with the respective secondary antibodies at room temperature (anti-rabbit IgG-HRP (sc-2034) 
and anti-goat IgG-HRP (sc-2020) secondary antibodies, 1: 5000 5% milk, Santa Cruz 
Biotechnology). After washing 3 x 10 minutes with TBS/0.1% Tween 20, immunoreactive bands 
were detected with SuperSignal West Femto Kit (Pierce, Thermo Scientific) on ChemiDoc XRS+ 
system (BioRad). The results of two independent protein extractions were quantified using the 
ImageJ software: the density of each band was measured and the correspondent value was 
divided by the Actin (loading control) value. Calculation of cleaved protein was performed as 
follows:  Cleaved band/ (Total band + Cleaved band).  
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2.9. Wound-Healing Assay 
 
Cell migration was assessed by the wound-healing assay, which mimics cell migration 
during wound-healing in vivo. The principle is based in creating a scratch, simulating a wound 
in a cell monolayer, and capturing the images at the beginning and at regular intervals during 
cell migration to close the wound.  
 
MDA-MB-468, MDA-MB-231, Hs578T and MCF-7/AZ were plated in 6-well plates at a 
density of 2.8x106, 1x106 and 1.3x106cells/2ml, respectively, and grown overnight at 37C in a 
5% CO2 humidified atmosphere. Two wounds were created in confluent cells by manual 
scratching with 200µl pipette tip. The cells were gently washed 2 times with 1X PBS and were 
treated with Quercetin and Lonidamine at the respective IC50 or DMSO (control), during 24 
hours. At 0, 12 and 24 hours specific wound sites (two sites for each wound) were 
photographed at 100X magnification using an Olympus IX51 inverted microscope equipped 
with an Olympus DP20 Digital Camera System. Evaluation of migration distances (5 measures 
per wound) were performed with the MeVisLab platform and percentage of cell migration 
relative to control was evaluated with the GraphPad Prism 5 software. At least three 
independent experiments were conducted.  
 
 
2.10. Invasion assay 
 
Cell invasion was evaluated by using 24-well BD BioCoat Matrigel Invasion Chambers, with 
8μm pore size PET membrane (BD Biosciences). These invasion chambers provide cells with 
specific conditions that allow their invasive behavior in vitro: the thin layer of Matrigel Matrix 
mimics a basal membrane that occludes the pores of the PET membrane, blocking non-
invasive cells from migrating through the membrane.  In contrast, invasive cells are able to 
detach themselves and invade through the Matrigel Matrix and the 8μm membrane pore.  
 
Matrigel Invasion Chambers were rehydrated with serum free culture media (500µl for the 
interior of the insert and 500µl into the well) for 2 hours at 37C, 5% CO2 atmosphere.  
After rehydration, the medium was removed from both insert and well, and 750µl of complete 
medium with 10%FBS was added into the well (chemoattractant). Cellular suspensions (500µl) 
were added to each insert - 5x104/ml (MDA-MB-231, Hs578T and MCF-7/AZ) and 8x104/ml 
(MDA-MB-468), in serum free culture medium with Quercetin and Lonidamine IC50 or DMSO 
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(control). After 24 hours of incubation, non-invading cells were removed from the upper 
surface of the membrane by scrubbing with a swab. In a new 24-well plate, the invasive cells 
on the lower surface of the membrane were fixed and stained with 100% methanol and 
hematoxylin, respectively, for 2 minutes in each solution. The inserts were rinsed twice in 
distilled water to remove excess stain and allowed to air dry during 1-2 hours. To count the 
invading cells, membranes were removed and placed on a microscope slide with glycerol. 
Whole membranes were photographed at 16X and 25X magnifications using an Olympus SZx16 
stereomicroscope with an Olympus DP71 digital camera system, and also at 100X 
magnification using an Olympus Bx61 microscope with an Olympus DP70 digital camera 
system. The percentage of invasive cells resulting from two independent experiments was 
evaluated with the GraphPad Prism 5 software. 
 
 
 
2.11. Statistical Analysis 
 
All graphs and statistical analysis were performed with the Graph Pad Prism 5 software. 
Statistical significance was assessed by the t-test and results are presented as normalized 
means ± SD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3
 
 Results 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Results 
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
45 
3.1. Characterization of protein expression in Breast Cancer Cell lines 
 
Expression of MCT1, MCT4, CD147 and Hexokinase II was evaluated by 
immunocytochemistry in human breast cancer cell lines (MDA-MB-468, MDA-MB-231, Hs578T, 
BT20, MCF-7/AZ and SkBr3), as shown in Figure 13. 
 
Figure 13: Immunocytochemical expression of different proteins in human breast carcinoma cell lines 
(400x magnification). 
 
Membrane expression of MCT1 was only observed in MDA-MB-468, Hs578T and BT20 cell 
lines, while MCT4 was expressed in the plasma membrane of MDA-MB-231 and SkBr3 at and 
at low levels in the cytoplasm of MDA-MB-468, Hs578T and MCF-7/AZ. MDA-MB-231 was 
negative for MCT1 expression, while BT20 was negative for MCT4 expression.  CD147 was 
observed in the plasma membrane of all cell lines studied, however, MDA-MB-468, Hs578T 
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and MCF-7/AZ expressed this protein at very low levels. Hexokinase II, a cytoplasmic protein, 
was expressed at high levels in MDA-MB-468 and MDA-MB-231 cell lines. It was also observed 
in MCF-7/AZ and SkBr3, but at very low levels, while it was absent in Hs578T and BT20 cell 
lines. 
 
3.2. Effect of Quercetin and Lonidamine on cell survival 
 
The MCT inhibitors Quercetin and Lonidamine were used to access the effect of blocking 
lactate transport on cell survival. The IC50 for each cell line was determined by the SRB assay in 
which total cell biomass was quantified.  
Cells were treated with different concentrations of Quercetin (20, 50, 100 and 200µM) 
(Figure 14) and Lonidamine (100, 200, 300 and 400µM) (Figure 15) for 24, 48 and 72 hours. 
This first assay was performed to select the range of concentrations and the optimal time of 
exposure for subsequent assays.  
In this first screen (Figure 14 and 15), Quercetin and Lonidamine decreased the percentage 
of viable cells in a dose- and time-dependent, decreasing the percentage of viable cells in all 
cell lines, except for Quercetin treatment in BT20 cell line. 
 
 
 
Figure 14: Effect of Quercetin on total cell biomass, for 24, 48 and 72 hours. Results are expressed as 
mean ± SD. 
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Figure 15: Effect of Lonidamine on total cell biomass, for 24, 48 and 72 hours. Results are expressed as 
mean ± SD. 
 
 
Based on the previous results, the range of concentrations was adjusted to calculate the 
IC50 for both inhibitors (10, 20, 50 and 100µM for Quercetin and 50, 100, 200 and 300µM for 
Lonidamine). The time for incubation selected for both inhibitors was 48 hours. The results are 
shown in Figure 16 and 17. 
 
Figure 16: Effect of Quercetin on total cell biomass (48hours incubation). Results are expressed as mean 
± SD of at least three independent experiments. 
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Figure 17: Effect of Lonidamine on total cell biomass (48hours incubation). Results are expressed as 
mean ± SD of at least three independent experiments. 
 
For both inhibitors MDA-MB-468, MDA-MB-231 and Hs578T seem to be the most sensitive 
cell lines (Figure 16 and 17, Table 4). These cell lines present an IC50 for Quercetin between 40 
and 50µM, while for Lonidamine the estimated IC50 values were between 100 and 125µM.  
MCF-7/AZ cell line was sensitive only to Lonidamine, with a IC50 of approximately 125µM. Even 
though BT20 and SkBr3 were the less sensitive to Quercetin and Lonidamine, the highest IC50 
of the other cell lines was used in the subsequent assays (namely metabolism) (see Table 4). 
 
Table 4: IC50 values for Quercetin and Lonidamine for each cell line. 
 
 
 
 
 
 
 
 
*- These values do not correspond to the IC50 value. For these cell lines, the highest IC50 value for the 
other cell lines was used. 
 
Quercetin Lonidamine 
IC50 value 
calculated 
IC50 value used 
IC50 value 
calculated 
IC50 value used 
MDA-MB-468 49.64 µM 50 µM 95.84 µM 100 µM 
MDA-MB-231 40.65 µM 40 µM 126.1 µM 125 µM 
Hs578T 39.88 µM 40 µM 124.5 µM 125 µM 
BT20 >100 µM 50 µM* >300 µM 125 µM* 
MCF-7/AZ >100 µM 50 µM* 123.6 µM 125 µM 
SkBr3 94.05 µM 50 µM* 237.8 µM 125 µM* 
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Microscopically, morphological alterations were detected at 48 hours after treatment with 
the respective IC50 (Table 4) for each cell line (Figure 18). Both inhibitors induced cell 
phenotypic alterations, being Quercetin the one that had a more drastic effect. For MDA-MB-
468 and Hs578T, mainly for Quercetin, a large fragmentation of cells was observed and in the 
remaining cells the shape was more elongated.  BT20 was not very susceptible to phenotypic 
alterations, only some cellular fragments were observed for Lonidamine. 
 
Figure 18: Morphological aspect of breast cancer cell lines with DMSO (control) and with the respective 
IC50 for Quercetin and Lonidamine (48hours incubation). 
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3.3. Effect of  Quercetin and Lonidamine on cell metabolism 
 
Glucose consumption and lactate production were evaluated during inhibition in order to 
understand if the inhibitory effect in total cell biomass, induced by both inhibitors was due to 
metabolic alterations. The different cell lines were treated with the respective IC50 values for 
Quercetin and Lonidamine for 24h, and extracellular amounts of glucose and lactate were 
measured in control (DMSO) and treated cells.  
The metabolism assay showed that, after 24h, only in MDA-MB-468 (Figure 19A; 20A) and 
Hs578T cell lines (Figure 19C; 20C), presented a significant decrease a significant decrease in 
glucose consumption and lactate production for both inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Effect of Quercetin and Lonidamine on glucose consumption (24 hours treatment). Results 
are presented as mean ± SD of at least three independent experiments.  p<0.05; *Control (DMSO) vs 
Quercetin; ** Control (DMSO) vs Lonidamine. 
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In MDA-MB-468 cell line the amount of glucose consumed after inhibition was reduced to 
half (6mM to 3mM, approximately) and lactate was reduced from 7mM (control) to around 
4mM (treated cells). Glucose consumed by Hs578T in control cells (4.5mM) was decreased to 
approximately 2.5mM after treatment with both inhibitors, while lactate was reduced from 
4.5mM (control) to 2.8mM (treated cells).  
In the MDA-MB-231 cell line, both Quercetin and Lonidamine decreased significantly the 
amount of glucose consumed relatively to control (DMSO) (Figure 19B), however, this 
alteration was not accompanied by a decrease in lactate production (Figure 20B). 
 
Figure 20: Effect of Quercetin and Lonidamine in lactate production (24 hours treatment). Results are 
presented as mean ± SD of at least three independent experiments.  p<0.05; *Control (DMSO) vs 
Quercetin; ** Control (DMSO) vs Lonidamine. 
A B 
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In opposition, for BT20 cell line, Quercetin increased glucose consumption (Figure 19D), 
while lactate production decreased (Figure 20D).   
In MCF-7/AZ cell line, only Lonidamine decrease glucose consumption and lactate 
production, soon after 4 hours (Figure 19E; 20E). 
SKBR3 cell metabolism was not affected by both inhibitors (Figure 19F; 20F). 
 
For the following assays, some cell lines were selected based on the previous results: 
Three basal-like cell lines – (MDA-MB-468 and Hs578T which presented inhibition of glycolitic 
metabolism for both inhibitors and MDA-MB-231, which metabolism was not altered but the 
sensitivity to both inhibitors was high).and a luminal cell line (MCF-7/AZ, which metabolism 
was affected only for Lonidamine).  
 
3.4. Effect of Quercetin and Lonidamine on cell proliferation 
Aiming to evaluate the role of MCT activity inhibition on cell proliferation, cells were 
treated with the IC50 value for Quercetin and Lonidamine, for 24 and 48 hours, and BrdU 
incorporation into DNA was measured.  
 
       
       
Figure 21: Effect of Quercetin and Lonidamine on cell proliferation (24 and 48 hours treatment). Results 
are presented as mean ± SD of at least three independent experiments.  *p<0.05 compared to control 
(DMSO). 
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As shown in Figure 21, Quercetin and Lonidamine induced a significant decrease in cell 
proliferation in a time dependent manner for MDA-MB-468, MDA-MB-231 and Hs578T (Figure 
20A; 20B; and 20C, respectively). In the three cell lines, the highest effect was observed for 
Lonidamine with about 60-70% of cell proliferation inhibition at 48 hours, while for Quercetin 
it was approximately 40-50%. A smaller effect was observed for MCF-7/AZ cells that only after 
48 hours of treatment with Lonidamine induced a significant decrease (30%) in cell 
proliferation (Figure 20D). 
 
 
3.5. Effect of Quercetin and Lonidamine on cell death 
 
To study the effect of Quercetin and Lonidamine on apoptosis/necrosis due to MCT activity 
inhibition, cells were treated with the respective IC50 values for 48 hours and were stained with 
Annexin V/PI and analyzed by flow cytometry.  Also, cleavage of caspase-3 and PARP was 
evaluated by Western blot to confirm the results of flow cytometry.  
 
 
 
Figure 22: Effect of Quercetin and Lonidamine on MDA-
MB-468 cell death (48 hours treatment), determined by 
Annexin V/PI staining. A) Representative flow cytometry 
dot plot. Similar dot plots were obtained in three 
independent experiments. B) Percentage of 
apoptotic/necrotic population. Results are presented as 
mean±SD of three independent experiments.  *p<0.05 
compared to control DMSO.  
 
A 
B 
Results   Chapter 3   
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
54 
In flow cytometry analysis (Figure 22), MDA-MB-468 cell line showed a basal level of cell 
death in the control (DMSO) (around 2% of apoptosis and 4.5% of necrosis), while cells treated 
with Quercetin exhibited a significant increase in the levels of necrosis to approximately 16%. 
However, with Lonidamine treatment, there was no significant increase in cell death (about 
10% of total death), relative to control (DMSO). 
By Western blot analysis, the basal levels of apoptosis previously observed in the control 
(DMSO) (Figure 22B), were not detected in caspase-3 blot and only a weak band of cleaved 
PARP was observed (Figure 23A). However, when cells were treated with Quercetin or 
Lonidamine, cleaved caspase-3 and PARP were observed (Figure 23A; 23B). 
 
Figure 23: Effect of Quercetin and Lonidamine on MDA-MB-
468 cell death - caspase-3 and PARP activation (48 hours 
treatment) by Western blot analysis. A) Representative blot 
of Caspase-3 and PARP protein levels. Similar blots were 
obtained in the two independent experiments. B) Levels of 
cleaved caspase-3 and cleaved PARP. Results are presented as 
mean±SD of two independent experiments.   
 
 
 
 
MDA-MB-231 cells revealed some cell death levels already in the control (DMSO), mostly 
necrosis (10%), which remained in the Lonidamine treatment (Figure 24). In the case of 
Quercetin treatment, there was an increase in the necrotic population of about 7% relative to 
the control however it was not statistically significant (Figure 24B). By Western blot assay 
(Figure 25), treatment with Quercetin revealed a large amount of cleaved caspase-3 protein, as 
well as cleaved PARP. As expected, low levels of cleaved caspase-3 and cleaved PARP were 
detected in the blots of control (DMSO) and Lonidamine (Figure 25A). 
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Figure 24: Effect of Quercetin and Lonidamine on MDA-
MB-231 cell death (48 hours of treatment) determined 
by Annexin V/PI staining. A) Representative flow 
cytometry dot plot. Similar dot plots were obtained in 
three independent experiments. B) Percentage of 
apoptotic/necrotic population. Results are presented as 
mean±SD of three independent experiments.   
 
 
 
Figure 25: Effect of Quercetin and Lonidamine in MDA-MB-
231 cell death - caspase-3 and PARP activation (48 hours 
treatment) by Western blot analysis. A) Representative blot 
of Caspase-3 and PARP protein levels. Similar blots were 
obtained in the two independent experiments. B) Levels of 
cleaved caspase-3 and cleaved PARP. Results are presented 
as mean±SD of two independent experiments.  
 
As shown in Figure 26, Hs578T was the cell line with the highest levels of cell death 
compared with the other cell lines for both treatments. Quercetin treatment significant 
induced 30% of total death (17% of apoptosis and 14% of necrosis), whereas Lonidamine 
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significant induced 22% of total death (about 11% of both apoptosis and necrosis). Low levels 
of cell death were observed in the control (DMSO), only about 3.5% of apoptosis and 5.5% of 
necrosis. There was some level of cleaved caspase-3 with Quercetin and Lonidamine (Figure 
27), and the most remarkable effect was for PARP, which was almost totally cleaved (Figure 
27A). 
 
 
Figure 26: Effect of Quercetin and Lonidamine on 
Hs578T cell death (48 hours of treatment) determined 
by Annexin V/PI staining. A) Representative flow 
cytometry dot plot. Similar dot plots were obtained in 
three independent experiments. B) Percentage of 
apoptotic/necrotic population. Results are presented as 
mean±SD of three independent experiments.  *p<0.05 
compared to control (DMSO). 
 
 
 
Figure 27: Effect of Quercetin and Lonidamine on Hs578T cell 
death - caspase-3 and PARP activation (48 hours treatment) 
by Western blot analysis. A) Representative blot of Caspase-3 
and PARP protein levels. Similar blots were obtained in the 
two independent experiments. B) Levels of cleaved caspase-3 
and cleaved PARP. Results are presented as mean ± SD of two 
independent experiments.   
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As shown in Figure 28, Lonidamine neither induced a significant increase in cell death nor 
induced cleaved caspase-3 in the MCF-7/AZ cells (Figure 29A). However, for Lonidamine 
treatment cleavage of PARP was complete, with a significant increase relative to the control 
(DMSO). 
 
Figure 28: Effect of Lonidamine on MCF-7/AZ cell death (48 hours treatment) determined by Annexin 
V/PI staining. A) Representative flow cytometry dot plot. Similar dot plots were obtained in three 
independent experiments. B) Percentage of necrotic population. Results are presented as mean±SD of 
three independent experiments.   
 
 
 
Figure 29: Effect of Lonidamine on MCF-7/AZ cell death - caspase-3 and PARP activation (48 hours 
treatment) by Western blot analysis. A) Representative blot of Caspase-3 and PARP protein levels. 
Similar blots were obtained in the two independent experiments. B) Levels of cleaved caspase-3 and 
cleaved PARP. Results are presented as mean±SD of two independent experiments.  *p<0.05 compared 
to control (DMSO). 
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3.6. Effect of Quercetin and Lonidamine on cell migration 
 
To study the effect of Quercetin and Lonidamine on cell migration as a result of MCT 
inhibition, cells were treated with the respective IC50 values for 24 hours and the wound-
healing assay was performed.  
 
As shown in Figure 30, MDA-MB-468 cell line did not exhibit a high migratory capacity, 
nevertheless treatment with both inhibitors was able to significant decrease the percentage of 
cell migration relative to control (DMSO) (around 16% of migration).  However, Lonidamine 
demonstrated a higher efficacy in inhibiting cell migration (about 7%), compared to Quercetin 
(only 4%). 
 
MDA-MB-468 
  
Figure 30: Effect of Quercetin and Lonidamine on MDA-MB-468 cell migration (24 hours of treatment) 
by the wound-healing assay. Results are presented as mean±SD of at least three independent 
experiments.  *p<0.05 compared to control (DMSO). 
 
In MDA-MB-231 cell line, with a high migratory capacity, in the control (DMSO) more than 
60% of cell migration was observed after 24hours. In the presence of MCT inhibitors, the 
percentage of cell migration was significant reduced to more than half after 12 hours 
compared to DMSO, which was maintained after 24 hours (about 20% for Quercetin and 17% 
for Lonidamine) (Figure 31). 
Chapter 3  Results 
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
59 
MDA-MB-231 
  
Figure 31: Effect of Quercetin and Lonidamine on MDA-MB-231 cell migration (24 hours of treatment) 
by the wound-healing assay. Results are presented as mean±SD of at least three independent 
experiments.  *p<0.05 compared to control (DMSO). 
 
The same was observed for Hs578T cell line (Figure 32), in which cell migration was 
significant inhibited after treatment with Quercetin and Lonidamine. After 24 hours, cells only 
migrated around 12% for Quercetin and 16% for Lonidamine, while the control (DMSO) that 
migrated 44%. 
 
Hs578T 
  
Figure 32: Effect of Quercetin and Lonidamine on Hs578T cell migration (24 hours of treatment) by the 
wound healing assay. Results are presented as mean±SD of at least three independent experiments.  
*p<0.05 compared to control (DMSO). 
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Despite having a low migratory capacity MCF-7/AZ cell migration was also significantly 
inhibited by Lonidamine treatment after 24 hours, about 8% less than the control (DMSO) 
(Figure 33). 
 
MCF-7/AZ 
 
Figure 33: Effect of Lonidamine on MCF-7/AZ cell migration (24 hours treatment) by the wound healing 
assay. Results are presented as mean±SD of at least three independent experiments.  *p<0.05 compared 
to control (DMSO). 
 
 
3.7. Effect of Quercetin and Lonidamine on cell invasion 
 
To evaluate the consequence of glycolytic metabolism inhibition on cellular invasion, cells 
were treated with the respective IC50 values, for 24 hours, in matrigel invasion chambers.  
Although MDA-MB-468 and MDA-MB-231 cell lines have different invasive capacity, the 
same tendency was observed, as Lonidamine demonstrated a higher inhibitory effect for both. 
In MDA-MB-468, Quercetin significantly reduced the percentage of invasive cells about 22% 
relative to control (DMSO), however, a more drastic reduction (around 63%) was observed 
with Lonidamine treatment (Figure 34). In MDA-MB-231, the small decrease in invasive cells 
for Quercetin treatment was not significant, while Lonidamine significantly reduced about 50% 
the invasion capacity of these cells (Figure 35). 
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Figure 34: Effect of Quercetin and Lonidamine on MDA-MB-468 
cell invasion (24 hours treatment) by the matrigel invasion assay. 
Results are presented as mean±SD of two independent 
experiments.  *p<0.05 compared to control (DMSO). 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Effect of Quercetin and Lonidamine on MDA-MB-231 cell 
invasion (24 hours of treatment) by the matrigel invasion assay. 
Results are presented as mean±SD of two independent 
experiments.  *p<0.05 compared to control (DMSO). 
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Compared to the previous cell lines, Lonidamine showed a more moderate effect on 
Hs578T and MCF-7/AZ cells, significantly reducing invasion by 20-30% compared to control 
(DMSO) (Figure 36 and Figure 37). In Hs578T cell line, inhibition of invasion by Quercetin was 
similar to Lonidamine, decreasing around 26% comparing to control (DMSO). 
 
 
 
Figure 36: Effect of Quercetin and Lonidamine on Hs578T cell 
invasion (24 hours of treatment) by the matrigel invasion assay. 
Results are presented as mean±SD of two independent 
experiments.  *p<0.05 compared to control (DMSO). 
 
 
 
 
  
Figure 37: Effect of Lonidamine on MCF-7/AZ cell invasion (24 hours of treatment) by the matrigel 
invasion assay. Results are presented as mean±SD of two independent experiments.  *p<0.05 compared 
to control (DMSO). 
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Fast growing tumours, like breast carcinomas, display a markedly altered energy 
metabolism compared to normal tissue, in which tumour cells are able to increase the 
glycolitic capacity [134-135]. The consequent formation and accumulation of lactate, lead to 
an extracellular acidification, which eventually facilitates tumour growth invasion and 
metastasis. This feature makes “metabolic targeted therapy” a promising anti-cancer approach 
[134].  
It was previously described that there is up regulation of MCT1 in breast cancer, especially 
in high-grade tumours and in the basal-like subtype [123], which have a more aggressive 
clinical behaviour comparing to luminal and normal-like breast carcinomas [131, 136]. Since 
MCTs have been described as effective anti-cancer targets [3, 65, 137], it will be important to 
explore these molecules, especially MCT1, as therapeutic targets in breast cancer. In the 
present work, Quercetin and Lonidamine were used as inhibitors of MCT activity, particularly 
MCT1, always keeping in mind that these inhibitors also have other cellular targets, as 
mentioned previously.  
 
 
4.1. Quercetin and Lonidamine inhibit lactate efflux in cells with MCT1 
plasma membrane expression 
 
In the present work, the expression of some metabolic targets of Quercetin and 
Lonidamine were analysed by immunocytochemistry, in six human breast cancer cell lines. 
MCT1 plasma membrane expression was found in three basal-like subtype cell lines (MDA-MB-
468, Hs578T and BT20) as verified by Pinheiro and colleagues in human breast carcinoma 
samples [123]. In concordance with other published results, MCT1 was not found in the basal-
like subtype MDA-MB-231, since there is alteration in the gene promoter which leads to loss of 
protein expression [126]. Also, in the luminal subtype cell line- MCF-7/AZ and in the HER2 
positive cell line- SkBr3, expression of MCT1 was not observed. MCT4, which has been 
associated with high glycolitic tissues [33-34, 38], was strongly expressed at the plasma 
membrane in SkBr3 cell line as well as in MDA-MB-231, as verified by Gallagher and colleagues 
[75]. CD147 expression was also evaluated, since MCT1 and 4 isoforms require the association 
with this ancillary protein for plasma membrane translocation and activity [50, 73, 75]. 
Surprisingly, the cell lines expressing a strong MCT1 plasma membrane expression (MDA-MB-
468 and Hs578T), showed low CD147 expression. This can be explained by the presence of 
additional chaperones such as CD44, which was recently described as also being involved in 
MCT membrane localization [138-139]. Additionally, strong expression of Hexokinase II was 
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only observed in two basal-like subtype cell lines (MDA-MB-468; MDA-MB-231). Although 
other Hexokinase isoforms, namely isoform 1, have been associated with cancer cells [140], 
Hexokinase II has been frequently described as the major isoform expressed in cancers that 
exhibited a high glycolytic phenotype [99, 141]. So, the other cell lines that expressed low or 
no Hexokinase II may expresses other isoform, in order to maintain high rates of glycolysis.  
 
The inhibitory effect of Quercetin and Lonidamine on cell survival in human breast cancer 
cell lines was evaluated by SRB assay, a not so conventional method. Other conventional 
assays like MTT and MTS are not so adequate when MCT activity is inhibited, since metabolism 
is being targeted and these assays are based on the metabolic reduction of compounds [142]. 
SRB assay results showed that the breast cancer cell lines have different sensitivities to both 
inhibitors, which may be explained by the different pattern of protein expression previously 
described. 
MDA-MB-468 and Hs578T cells were sensitive to both inhibitors probably due to the high 
plasma membrane expression of MCT1, which is inhibited by Quercetin and Lonidamine [38, 
65, 78], likely decreasing the intracellular pH and leading to loss of viability [65]. However, 
MDA-MB-468 also presented high levels of Hexokinase II, which was described by some 
authors as a target of Lonidamine [98], but others describe Lonidamine as a strong inhibitor of 
lactate efflux, inducing intracellular acidification [65, 100-101]. As expected from MCT1 
inhibition, Quercetin and Lonidamine decreased the glycolytic metabolism of these cells, 
decreasing glucose consumption and lactate production. The inhibition of lactate efflux would 
promote intracellular accumulation of lactate which would induce glycolysis arrest, decreasing 
glucose uptake rates.  
Unexpectedly, MDA-MB-231 which does not express MCT1 was also very sensitive to both 
inhibitors. Also, this cell line showed a lower lactate production and subsequently a lower 
glucose uptake than the other cell lines. Also, this cell line showed high amounts of Hexokinase 
II that may be inhibited by Lonidamine, explaining the cytotoxic effect of this inhibitor, by 
decrease in glucose phosphorylation [98, 140], as demonstrated on cell metabolism assay.  
This observation led us to hypothesize that other metabolic pathways associated with tumour 
aggressiveness may be also important in these cells. As verified by others in breast cancer, 
prostate cancer, endometrial cancers, thyroid cancer and colorectal cancer, de novo fatty acid 
synthesis also provides precursor molecules for proliferation and differentiation pathways 
[127, 143-144]. De novo fatty acid synthesis involves the conversion of glucose into pyruvate, 
which enters in mitochondria to produce citrate necessary for fatty acid synthesis [127]. Thus, 
it is expected that glycolytic metabolism inhibition in these cells affects glucose uptake more 
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efficiently than lactate efflux. Quercetin was able to decrease glucose consumption, even in 
the absence of MCT1 expression, perhaps by inhibition of intracellular targets which regulate 
metabolic pathways, like PI3K-Akt pathway [84, 127, 144].  
As expected, MCF-7/AZ cells, estrogen receptor positive, were practically insensitive to 
Quercetin, since the putative target (MCT1) was not expressed, and subsequently glycolitic 
metabolism was not inhibited. However, Lonidamine led to a decrease in total cell biomass, as 
well as to inhibition of glycolytic metabolism (Figure 19E; Figure 20E) even without MCT1 
expression. As showed by Millon and colleagues, Hexokinase I can also be a target of 
Lonidamine, inhibiting glucose uptake, as indicated by the decrease in 2-NBDG (2-(N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) [140]. Expression of Hexokinase I was 
not evaluated in the present study, so it would be important, to verify if Lonidamine effect on 
MCF-7-7AZ is through inhibition of Hexokinase I. 
Moreover, BT20 cell line, positive for MCT1, was weakly sensitive to Quercetin and 
Lonidamine treatment, and the disturbance of metabolism was not as expected. Quercetin 
increased the levels of glucose uptake, however, less lactate was produced, indicating that 
other intermediates of glycolysis were probably used in other metabolic pathways (like 
pyruvate in oxidative phosphorylation), allowing the maintenance of cellular growth. 
Metabolism of SkBr3 cells, which were in the limit between sensitive and insensitive cell 
lines, was not affected by any of the inhibitors, which could be justified by the absence of 
expression of their targets.  
 
 
4.2. Quercetin and Lonidamine treatment decreased cell proliferation 
 
Since anti-tumour drugs often affect the proliferative capacity of the cells, cell death, as 
well as migration and invasion, the effect of Quercetin and Lonidamine was also assessed in 
this context. 
It is known that self-sufficiency in growth factors and insensitivity to anti-growth factors 
promote tumour cell proliferation, and there are multiple mechanisms through which 
constitutive activation of growth factor signals can be associated with metabolic 
reprogramming [7]. Glucose degradation provides cells with intermediates used for 
biosynthetic pathways, like biosynthesis of lipids, nucleotides and amino acids. Also, the high 
quantity of lactate produced may be a substrate for oxidative tumour cells [3, 145-146]. In the 
present study, Quercetin and Lonidamine decreased cell proliferation in a time-dependent 
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manner in the cell lines studied, while MCF-7/AZ cells were more resistant to proliferation 
inhibition. Another study demonstrated that Quercetin stimulated the proliferation of MCF-7 
cell line through estrogen receptor [147].  
With the decrease in glucose uptake, cells were starved of nutrients which led to inhibition 
of cell growth, probably by cell cycle arrest. Evidence points to Quercetin as an inducer of 
cytotoxic effects by cell cycle arrest at G1 and/or G2/M in cancer cells [148]. However, the 
chemopreventive effects of Quercetin have been attributed to interaction with direct 
molecular targets like PI3K, Raf-MEK and AKT [80, 148-149], molecular effectors of survival 
pathways [150]. Inhibition of endothelial cell proliferation by Lonidamine was observed by Del 
Bufalo and colleagues, and the authors hypothesized that inhibition of lactate transport and its 
intracellular accumulation would affect endothelial cell proliferation [103]. 
 
 
4.3. Quercetin and Lonidamine markedly induced cell death in MCT1 
positive cells 
 
To check if Quercetin and Lonidamine activity is mediated through induction of 
necrosis/apoptosis, the Annexin/PI assay and evaluation of cleaved caspase-3 and PARP were 
performed. 
Apoptosis is well defined by cell morphological changes including plasma membrane 
blebbing, chromatin condensation, nuclear fragmentation and formation of apoptotic bodies. 
Biochemical apoptosis is characterized by PS externalization to the outer leaflet of the plasma 
membrane, changes in mitochondrial membrane permeability, caspase-dependent activation 
and nuclear translocation of a caspase-activated DNase resulting in DNA cleavage. In contrast, 
necrosis is characterized by swelling of the cell and of the cytoplasmic organelles, and rapid 
loss of plasma membrane integrity. Since PS externalization is an early marker of apoptotic 
cells death, it can be detected by using annexin V, a Ca2
+ dependent phospholipid binding 
protein, conjugated with various fluorochromes, such as Alexa Fluor dyes. PI, a fluorescent 
membrane dye that stains nuclei, only enters in the cell if the cell membrane becomes 
permeable; it is widely used in cell death research to measure the integrity of the plasma 
membrane. Thus, Annexin V-Alexa Fluor with PI can help to distinguish between apoptosis and 
necrosis. During apoptosis, there is positivity to Annexin V-Alexa Fluor due to PS binding, while 
in necrotic cells both PS positivity and PI positivity coincide [151-152]. 
In the present study, Quercetin produced a higher effect on cell death than Lonidamine, 
which was accompanied by morphological alterations. However, in cells with high levels of 
Chapter 4   Discussion 
 
 
Monocarboxylate transporters as potential therapeutic targets in breast cancer: inhibition studies in vitro models 
69 
MCT1 and without Hexokinase II (Hs578T cells), the levels of necrosis and/or apoptosis were 
significantly higher for both inhibitors. This fact supports the hypothesis that inhibition of 
MCT1 induced cell cytotoxicity by inhibition of lactic acid export, which decreases intracellular 
pH in the more glycolytic cells. Western blot for activated caspase-3 and PARP confirmed the 
induction of apoptosis by Quercetin and Lonidamine. Concerning the other cell lines, only 
Quercetin significantly increased cell death in MDA-MB-468 cells, which may be due to 
inhibition of MCT1.  
However, the results of Western blot for caspase-3 and PARP for Quercetin were not in 
agreement with all the results obtained by flow cytometry. Quercetin induced a strong 
activation of caspase-3 and PARP in MDA-MB-468 and MDA-MB-231 cells, indicating apoptosis, 
which was not verified by flow cytometry for Annexin V/PI. 
Importantly, one problem of using adherent cells for flow cytometry is the tripsinization 
step, which may be critical to membrane integrity. After tripsinization, the cells treated with 
Quercetin may lose the membrane integrity promoting the entry of PI in the cells, which by 
flow cytometry was considered as necrotic population. In these cases, the activation of 
caspases allows to distinguish between apoptotic and necrotic cell death. However, additional 
assays could be performed in order to confirm the presence of apoptosis, such as 
demonstration of the internucleosomal DNA fragmentation in electrophoresis [151]. 
Other reports also showed that Quercetin induced apoptosis by the mitochondrial 
pathway, increasing cleaved caspase-8, -9 and -3 and down-regulated anti-apoptotic proteins 
(Bcl-XL and Bcl-2) [81, 84, 153].  In MCF-7/AZ cells apoptosis was not observed neither 
cleavage of caspase-3, but, surprisingly, cleaved PARP was observed. Lack of caspase-3 due to 
a functional deletion of CASP-3 gene and activation of apoptosis mediated by caspase-7 was 
described by others in MCF-7 cells [154]. Consequently, the activation of caspase substrate 
PARP probably can be via caspase -6 and -7 [155]. However, it was described in the literature 
that Lonidamine fails to activate the apoptotic process in MCF-7 cells because of the higher 
levels of anti-apoptotic bcl-2 protein [105]. Since PARP cleavage by lysosomal proteases was 
also observed in necrosis, producing a fragment of 50kDa, and the cleavage by caspases 
produce a fragment about 89kDa [156], the results obtained remain unclear and more 
experiments will be necessary to characterize the cell death mechanism in these cells, such as 
expression of other effector caspases. 
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4.4. Cell migration and invasion capacity was reduced by Quercetin and 
Lonidamine treatment 
 
Migration and invasion are two major steps in the metastatic cancer cascade, in which 
cancer cells are able to become motile to escape the primary tumour and move to a different 
location [157]. Thus, it was also important to evaluate the effect of Quercetin and Lonidamine 
in breast cancer cells in these two mechanisms. The results herein presented show that both 
inhibitors were efficient in inhibiting migration and invasion in all cell lines analyzed. There is 
evidence that tumour acidity due to efflux of lactate and H+ induces activation of matrix 
metaloproteinases and cathepsins, to degrade components of the basement membrane and 
the extracellular matrix [157-158]. With the exception of MDA-MB-231 cells, inhibition of 
lactate efflux was observed with both compounds, which may have reduced the activation of 
these proteases. Other findings demonstrated that Quercetin and Lonidamine are able to 
inhibit the expression of MMP-9 [91, 103], thereby enhancing the effect of lactate efflux 
inhibition.  
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Conclusion
 
The “Warburg effect” is currently considered as a new cancer hallmark [7], and MCTs are 
key players in the hyper-glycolytic and acid-resistant phenotypes, by adaptation to hypoxia and 
acidosis. 
In the present work was demonstrated that inhibition of MCT activity by Quercetin and 
Lonidamine have an inhibitory effect on breast cancer cell glycolitic metabolism especially in 
cell lines with MCT1 membrane expression. Consequently, the aggressiveness potential of 
these cells decreased by inhibition of proliferation, migration and invasion and by the 
increased in cell death. 
These data support the exploitation of MCTs as potential targets for breast cancer therapy, 
mainly in breast cancer basal-like subtype. 
Future Perspectives 
 
Importantly, many questions remain to be answered, so, additional experiments will be 
necessary to complement this work. 
We intend to better characterize the metabolism in breast cancer cell lines by evaluating 
other markers such as PDK, PFK, and LDH, as well as MCT2, which more efficiently uptake 
pyruvate and lactate to enter metabolic pathways others than glycolysis. 
Also, combinatory effects of MCT inhibition with other drugs actually used in breast cancer 
treatment (e.g. doxorubicin) will be necessary, since it can be advantageous to reduce the dose 
of classical drugs and decreasing drug resistance. 
Additionally, it will be essential to perform in vitro studies of MCT inhibition with other 
more particular approaches such as siRNA (expression inhibition) or specific MCT1 inhibitors 
(activity inhibition), like the ones developed by AstraZeneca, to confirm the results obtained. 
Evaluation of all the parameters presented in this thesis will be important, as well as 
evaluation of colony formation capacity, which evaluates the ability of cells to growth in an 
anchorage independent manner, correlating with the in vivo carcinogenic process and is very 
useful to measure cell sensitivity to several inhibitors.  
Since in vitro studies do not mimic all real tumour conditions, it will be fundamental to 
demonstrate the value of MCT inhibition (expression and activity) in animal models (mice), 
particularly MCT1 in a basal-like breast cancer model.  
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